

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 November 2005 (17.11.2005)

PCT

(10) International Publication Number  
**WO 2005/108603 A1**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/68**
- (21) International Application Number:  
PCT/EP2005/004839
- (22) International Filing Date: 4 May 2005 (04.05.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/569,220 6 May 2004 (06.05.2004) US  
60/599,318 5 August 2004 (05.08.2004) US
- (71) Applicant (for DE only): **ROCHE DIAGNOSTICS GMBH** [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).
- (71) Applicant (for all designated States except DE, US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HOLCOMB, Cherie** [US/US]; 3015 Partridge Ave, Oakland, CA 94605 (US). **HIGUCHI, Russell** [US/US]; 3258 Liberty Avenue, Alameda, CA 94501 (US). **SCHOENBRUNNER, Nancy** [US/US]; 746 Crossbrook Drive, Moraga, CA 94556 (US).
- (74) Agent: **ROCHE DIAGNOSTICS GMBH**; c/o Burger, Alexander, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**  
— of inventorship (Rule 4.17(iv)) for US only
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 2005/108603 A1**

(54) Title: SENP1 AS A MARKER FOR CANCER

(57) Abstract: The present invention provides methods of detecting cancer cells by detecting the quantity of SENP1 and/or telomerase in a sample.

## SENP1 AS A MARKER FOR CANCER

### Field of the invention

The present invention provides methods of detecting cancer cells by detecting the quantity of SENP1 and/or telomerase in a sample.

5

### BACKGROUND OF THE INVENTION

Most cells in the normal adult human body do not divide. Cancer cells, however, escape growth regulation and divide unrestrained. To do this, they must replicate their chromosomes including the ends of these chromosomes, called telomeres.

10 Activation of the enzyme, telomerase, which adds telomeric sequence to chromosomal ends (reviewed in Collins, K., *Curr. Opin Cell Biol.* 12 (2000) 378-383) can overcome this senescence. See, Bodnar, A.G., *et al.*, *Science* 279 (1998) 349-352; reviewed in De Lange, T., *Science* 279 (1998) 334-335). Cell lines with active telomerase become immortalized. *In vivo*, previously senescent cells with active telomerase grow into tumors. Telomerase activity has been detected in  
15 essentially all major types of cancer (Shay, J.W. and Bacchetti, S., *Eur. J. Cancer*, 33 (1997) 787-791; Cong, Y.S., *et al.*, *Microbiol. Mol. Biol. Rev.* 66 (2002) 407-425). Hanahan and Weinberg have named the expression of the telomerase catalytic subunit as one of the six key events common to cancer (*Cell* 100 (2000) 57-70). Expression of the genes coding for telomerase (TERT and TERC) has been  
20 proposed as a molecular marker for the diagnosis, monitoring, and prognosis of cancer.

However, not all tumors of a given cancer type contain detectable levels of telomerase activity. See, *e.g.*, Shay, J.W. and Bacchetti, S. *Eur. J. Cancer*, 33 (1997) 787-791); Yan, P. *et al.* *Cancer Res.* 59 (1999) 3166-3170. It is therefore  
25 important to identify molecular markers that identify tumors immortalized by a telomerase independent mechanism.

### BRIEF SUMMARY OF THE INVENTION

30 The present invention provides data demonstrating that there is an association of bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer and the quantity of SENP1

- 2 -

expression. Thus, SENP1 provides a useful marker for the detection of bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer cancers.

5 In some embodiments, the present invention provides methods of detecting SENP1 expression in a biological sample. In some embodiments, the methods comprise determining the quantity of SENP1 in a biological sample from an individual having or suspected of having a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

10 In some embodiments, the methods comprise determining the quantity of SENP1 in a biological sample from an individual; and recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

15 In some embodiments, the methods comprise determining the quantity of SENP1 in a biological sample from an individual, wherein the biological sample is selected from the group consisting of a breast biopsy, a colon biopsy, a kidney biopsy, a lung biopsy, an ovary biopsy, a pancreas biopsy, a small intestine biopsy, a bronchial lavage and a stool. In some embodiments, the methods further comprise recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

20 In some embodiments, the method further comprises obtaining the biological sample from the individual.

25 In some embodiments, the methods further comprise recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

30 In some embodiments, the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample. In some embodiments, the sequence of the polynucleotide is determined. In some embodiments, the detection step comprises amplifying the polynucleotide in an amplification reaction. In some embodiments, the amplification reaction comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10

- 3 -

contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1. In some embodiments, the amplification reaction is a quantitative amplification reaction. In some embodiments, the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. In some embodiments, the detectably-labeled oligonucleotide comprises a fluorescent moiety. In some embodiments, the detectably-labeled oligonucleotide comprises a quencher moiety. In some embodiments, the amplification reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide. In some embodiments, the amplification reaction is a reverse transcriptase polymerase chain reaction (RT-PCR). In some embodiments, the RT-PCR reaction is a quantitative RT-PCR reaction. In some embodiments, the quantity of the polynucleotide is normalized.

In some embodiments, the quantity of SENP1 is determined by detecting a SENP1 polypeptide in the sample. In some embodiments, the polypeptide is detected by contacting the polypeptide with an antibody.

In some embodiments, SENP1 is detected by detecting SENP1 activity.

In some embodiments, the method further comprises determining the quantity of telomerase in the biological sample. In some embodiments, telomerase is detected by detecting telomerase activity. In some embodiments, telomerase activity is detected by detecting elongation of an oligonucleotide comprising two or more repeats of TTAGG.

In some embodiments, telomerase is detected by detecting a component of telomerase in the sample. In some embodiments, the component is human telomerase RNA (TERC). In some embodiments, the component is human telomerase reverse transcriptase protein (TERT). In some embodiments, telomerase is detected by detecting human telomerase reverse transcriptase protein (TERT) mRNA. In some embodiments, the method comprises amplifying a SENP1 polynucleotide and a telomerase polynucleotide in a multiplex amplification reaction. In some embodiments, the telomerase polynucleotide is

- 4 -

human telomerase RNA (TERC). In some embodiments, the telomerase polynucleotide is human telomerase reverse transcriptase protein (TERT) mRNA. In some embodiments, the method further comprises comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells. In some embodiments, the standards are pre-determined values. In some embodiments, the individual is a human. In some embodiments, the method further comprises recording a prognosis for cancer treatment and/or survival for the individual. In some embodiments, the method further comprises recording the progression of cancer in the individual.

The present invention also provides methods for identifying an SENP1 antagonist. In some embodiments, the methods comprise contacting a plurality of agents to a cell expressing SENP1, wherein the cell does not express telomerase and the cell expresses a neoplastic phenotype, and selecting an agent that inhibits a neoplastic phenotype, thereby identifying an SENP1 antagonist. In some embodiments, the cell does not express TERT. In some embodiments, the methods further comprise testing the effect of the selected agent on cancer cells selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer. In some embodiments, the neoplastic phenotype is neoplastic cell growth. In some embodiments, the neoplastic phenotype is expression of a polypeptide or RNA associated with neoplastic growth. In some embodiments, the cell endogenously expresses SENP1. In some embodiments, the cell comprises an exogenous expression cassette encoding SENP1.

The present invention also provides methods of treating an individual having a cancer. In some embodiments, the methods comprise administering to a human a therapeutic amount of an antagonist of SENP1, wherein the individual has a cancer characterized by increased expression of SENP1 compared to non-cancer cells. In some embodiments, the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer. In some embodiments, the antagonist

- 5 -

is identified by the steps of: contacting a plurality of agents to a cell expressing SENP1, wherein the cell does not express telomerase and the cell expresses a neoplastic phenotype, and selecting an agent that inhibits a neoplastic phenotype, thereby identifying an SENP1 antagonist. In some embodiments, a pharmaceutical composition is provided comprising an antagonist of SENP1 and a  
5 pharmaceutically acceptable carrier. In some embodiments an antagonist of SENP1 is provided for use in medicine. In some embodiments an antagonist of SENP1 is used in the manufacture of a medicament or for manufacturing a medicament for the treatment of cancer, in particular breast cancer, colon cancer, kidney cancer,  
10 lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

Particularly preferred is bladder cancer.

The present invention also provides inhibitors of SENP1 protease activity. In some embodiments, the inhibitors comprise an amino acid sequence comprising Glu-Gln-Thr-Gly-Gly, or a mimetic thereof, wherein the final Gly terminates in an aldehyde.  
15 In some embodiments, the inhibitor comprises a nuclear localization signal sequence. In some embodiments, the nuclear localization signal sequence comprises Pro-Lys-Lys-Thr-Gln-Arg-Arg.

The present invention also provides for determination of the quantity of SENP1 and telomerase in a biological sample from an individual. In some embodiments, the  
20 quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample. In some embodiments, the polynucleotide is RNA.

In some embodiments, the sequence of the polynucleotide is determined. In some embodiments, the detection step comprises amplifying the polynucleotide in an amplification reaction. In some embodiments, the amplification reaction comprises  
25 at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1. In some embodiments, the amplification reaction is a quantitative amplification reaction. In some embodiments, the  
30 amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. In some embodiments, the detectably-labeled oligonucleotide comprises a fluorescent

- 6 -

moiety. In some embodiments, the detectably-labeled oligonucleotide comprises a quencher moiety. In some embodiments, the amplification reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled  
5 oligonucleotide.

In some embodiments, the amplification reaction is a reverse transcriptase polymerase chain reaction (RT-PCR). In some embodiments, the RT-PCR reaction is a quantitative RT-PCR reaction.

In some embodiments, the quantity of the polynucleotide is normalized.

10 In some embodiments, the quantity of SENP1 is determined by detecting a SENP1 polypeptide in the sample. In some embodiments, the polypeptide is detected by contacting the polypeptide with an antibody

In some embodiments, SENP1 is detected by detecting SENP1 activity.

15 In some embodiments, telomerase is detected by detecting telomerase activity. In some embodiments, telomerase activity is detected by detecting elongation of an oligonucleotide comprising two or more repeats of TTAGG.

In some embodiments, telomerase is detected by detecting a component of telomerase in the sample. In some embodiments, the component is human telomerase RNA (TERC). In some embodiments, the component is human  
20 telomerase reverse transcriptase protein (TERT).

In some embodiments, telomerase is detected by detecting human telomerase reverse transcriptase protein (TERT) mRNA.

25 In some embodiments, the method comprises amplifying a SENP1 polynucleotide and a telomerase polynucleotide in a multiplex amplification reaction. In some embodiments, the telomerase polynucleotide is human telomerase RNA (TERC).

In some embodiments, the telomerase polynucleotide is human telomerase reverse transcriptase protein (TERT) mRNA.

30 In some embodiments, the methods further comprise comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard representing SENP1 and telomerase quantities in non-cancer cells. In some embodiments, the standards are pre-determined values.

In some embodiments, the individual is a human.

- 7 -

In some embodiments, the biological sample comprises a bodily fluid. In some  
embodiments, the bodily fluid is blood. In some embodiments, the bodily fluid is  
urine. In some embodiments, the sample is from a tissue biopsy. In some  
embodiments, the method further comprises obtaining a biological sample from the  
5 individual.

In some embodiments, the individual has or is suspected of having cancer. In some  
embodiments, the cancer is bladder cancer.

In some embodiments, the method further comprises recording a diagnosis of the  
presence or absence of cancer in the individual. In some embodiments, the method  
10 further comprises recording a prognosis for cancer treatment and/or survival for the  
individual. In some embodiments, the method further comprises recording the  
progression of cancer in the individual. In some of these embodiments, the cancer  
is bladder cancer.

The present invention also provides kits for detecting a cancer cell in a biological  
15 sample from an individual. In some embodiments, the kit comprises

a) at least one oligonucleotide comprising a sequence at least 90% identical  
to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof,  
such that when the oligonucleotide and a polynucleotide comprising SEQ ID NO:1  
are submitted to an amplification reaction, the oligonucleotide primes amplification  
20 of at least a fragment of SEQ ID NO:1;

b) a detectably-labeled oligonucleotide comprising a sequence at least 90%  
identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement  
thereof;

c) at least one oligonucleotide comprising a sequence at least 90% identical  
25 to at least 10 contiguous nucleotides of:

- i) human telomerase RNA (TERC);
- ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- iii) a complement of TERC; or
- iv) a complement of TERT;

30 such that when the oligonucleotide and TERC or TERT mRNA are submitted to an  
amplification reaction, the oligonucleotide primes amplification of at least a  
fragment of TERC or TERT mRNA; and

- 8 -

d) a detectably-labeled oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:

- i) human telomerase RNA (TERC);
- ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- 5 iii) a complement of TERC; or
- iv) a complement of TERT.

In some embodiments, the kits comprise at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that when the oligonucleotides and a polynucleotide comprising SEQ ID NO:1 are submitted to an amplification reaction, the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1; and at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:

- i) human telomerase RNA (TERC);
- 15 ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- iii) a complement of TERC; or
- iv) a complement of TERT;

such that when the oligonucleotides and TERC or TERT mRNA are submitted to an amplification reaction, the oligonucleotides prime amplification of at least a fragment of TERC or TERT mRNA.

In some embodiments, the kit further comprises reverse transcriptase. In some embodiments, the kit further comprises a thermostable DNA polymerase.

In some embodiments, the detectably-labeled oligonucleotides comprises a fluorescent moiety. In some embodiments, the detectably-labeled oligonucleotides comprises quencher moiety.

The present invention also provides reaction mixture. In some embodiments, the reaction mixture comprises:

- a) at least one oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that when the oligonucleotide and a polynucleotide comprising SEQ ID NO:1 are submitted to an amplification reaction, the oligonucleotide primes amplification of at least a fragment of SEQ ID NO:1;

- 9 -

- b) a detectably-labeled oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof;
- c) at least one oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:
- i) human telomerase RNA (TERC);
  - ii) human telomerase reverse transcriptase protein (TERT) mRNA;
  - iii) a complement of TERC; or
  - iv) a complement of TERT;
- 10 such that when the oligonucleotide and TERC or TERT mRNA are submitted to an amplification reaction, the oligonucleotide primes amplification of at least a fragment of TERC or TERT mRNA; and
- d) a detectably-labeled oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:
- 15 i) human telomerase RNA (TERC);
  - ii) human telomerase reverse transcriptase protein (TERT) mRNA;
  - iii) a complement of TERC; or
  - iv) a complement of TERT.

In some embodiments, the reaction mixture comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that when the oligonucleotides and a polynucleotide comprising SEQ ID NO:1 are submitted to an amplification reaction, the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1; and at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:

- 25 i) human telomerase RNA (TERC);
- ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- iii) a complement of TERC; or
- iv) a complement of TERT;

30 such that when the oligonucleotides and TERC or TERT mRNA are submitted to an amplification reaction, the oligonucleotides prime amplification of at least a fragment of TERC or TERT mRNA.

- 10 -

In some embodiments, the reaction mixture further comprises a reverse transcriptase. In some embodiments, the reaction mixture further comprises a thermostable DNA polymerase. In some embodiments, the reaction mixture further comprises the detectably-labeled oligonucleotides comprises a fluorescent moiety.

5 In some embodiments, the reaction mixture further comprises the detectably-labeled oligonucleotides comprises quencher moiety.

The present invention also provides for determination of the quantity of SENP1 and telomerase in a biological sample from an individual. In some embodiments, the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in  
10 the sample. In some embodiments, the polynucleotide is RNA.

In some embodiments, the sequence of the polynucleotide is determined. In some embodiments, the detection step comprises amplifying the polynucleotide in an amplification reaction. In some embodiments, the amplification reaction comprises at least two different oligonucleotides comprising a sequence at least 90% identical  
15 to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1. In some embodiments, the amplification reaction is a quantitative amplification reaction. In some embodiments, the amplification product of the amplification reaction is detected in a step comprising  
20 hybridizing a detectably-labeled oligonucleotide to the product. In some embodiments, the detectably-labeled oligonucleotide comprises a fluorescent moiety. In some embodiments, the detectably-labeled oligonucleotide comprises a quencher moiety. In some embodiments, the amplification reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under  
25 conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide.

In some embodiments, the amplification reaction is a reverse transcriptase polymerase chain reaction (RT-PCR). In some embodiments, the RT-PCR reaction is a quantitative RT-PCR reaction.

30 In some embodiments, the quantity of the polynucleotide is normalized.

- 11 -

In some embodiments, the quantity of SENP1 is determined by detecting a SENP1 polypeptide in the sample. In some embodiments, the polypeptide is detected by contacting the polypeptide with an antibody

In some embodiments, SENP1 is detected by detecting SENP1 activity.

5 In some embodiments, telomerase is detected by detecting telomerase activity. In some embodiments, telomerase activity is detected by detecting elongation of an oligonucleotide comprising two or more repeats of TTAGG.

10 In some embodiments, telomerase is detected by detecting a component of telomerase in the sample. In some embodiments, the component is human telomerase RNA (TERC). In some embodiments, the component is human telomerase reverse transcriptase protein (TERT).

In some embodiments, telomerase is detected by detecting human telomerase reverse transcriptase protein (TERT) mRNA.

15 In some embodiments, the method comprises amplifying a SENP1 polynucleotide and a telomerase polynucleotide in a multiplex amplification reaction. In some embodiments, the telomerase polynucleotide is human telomerase RNA (TERC).

In some embodiments, the telomerase polynucleotide is human telomerase reverse transcriptase protein (TERT) mRNA.

20 In some embodiments, the methods further comprise comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard representing SENP1 and telomerase quantities in non-cancer cells. In some embodiments, the standards are pre-determined values.

In some embodiments, the individual is a human.

25 In some embodiments, the biological sample comprises a bodily fluid. In some embodiments, the bodily fluid is blood. In some embodiments, the bodily fluid is urine. In some embodiments, the sample is from a tissue biopsy. In some embodiments, the method further comprises obtaining a biological sample from the individual.

In some embodiments, the individual has or is suspected of having cancer.

30 In some embodiments, the cancer is bladder cancer.

In some embodiments, the method further comprises recording a diagnosis of the presence or absence of cancer in the individual. In some embodiments, the method

- 12 -

further comprises recording a prognosis for cancer treatment and/or survival for the individual. In some embodiments, the method further comprises recording the progression of cancer in the individual. In some of these embodiments, the cancer is bladder cancer.

5

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a typical receiver-operator curve of SENP1 mRNA from telomerase negative bladder cancer patient urine sediment and from healthy subject's urine sediment.

10 Figure 2 depicts a receiver-operator curve of SENP1 normalized to the housekeeping gene protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA).

Figures 3A and 3B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal bladder tissue and bladder tumor tissue.

15 For convenience of graphing on the same axis, TERT expression has been multiplied by a factor of  $1 \times 10^5$ .

Figures 4A and 4B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal breast tissue and breast tumor tissue. For convenience of graphing on the same axis, TERT expression has been multiplied

20 by a factor of  $1 \times 10^4$ .

Figures 5A and 5B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal colon tissue and colon tumor tissue. For convenience of graphing on the same axis TERT expression has been multiplied by a factor of  $1 \times 10^3$ .

25 Figures 6A and 6B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal kidney tissue and kidney tumor tissue. For convenience of graphing on the same axis, TERT expression has been multiplied by a factor of  $1 \times 10^4$ . Note that sample #3 has a value that falls off the linear scale shown.

30 Figures 7A and 7B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal lung tissue and lung tumor tissue. For convenience of graphing on the same axis, TERT expression has been multiplied

- 13 -

by a factor of  $1 \times 10^4$ . Note that sample # 1 and #20 have values that fall off the linear scale as shown.

Figures 8A and 8B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal ovarian tissue and ovarian tumor tissue.

5 For convenience of graphing on the same axis, TERT expression has been multiplied by a factor of  $1 \times 10^5$ .

Figures 9A and 9B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal pancreatic tissue and pancreatic tumor tissue. For convenience of graphing on the same axis, TERT expression has been

10 multiplied by a factor of  $1 \times 10^5$ .

Figures 10A and 10B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal pancreatic tissue (second set) and pancreatic tumor tissue (second set). For convenience of graphing on the same axis TERT expression has been multiplied by a factor of  $1 \times 10^4$ .

15 Figures 11A and 11B depict the expression level of SENP1 and TERT relative to adjusted GAPDH expression in normal small intestine tissue and small intestine tumor tissue. For convenience of graphing on the same axis TERT expression has been multiplied by a factor of  $1 \times 10^3$ .

## 20 DEFINITIONS

"**SENP1**" refers to a sentrin/SUMO-specific protease polypeptide or a polynucleotide encoding the polypeptide. Exemplary SENP1 polynucleotides include, e.g., Genbank accession number NM\_014554 (SEQ ID NO:1). Exemplary SENP1 polypeptides include, e.g., the polypeptide depicted in Genbank accession

25 number NP\_055369 (SEQ ID NO:2). "SENP1" is intended to encompass allelic variants of those sequences specifically provided herein, as well as fragments and mutations thereof. SENP1 polynucleotides will generally be at least 90%, 95% or 99% identical to SEQ ID NO:1 or 90%, 95% or 99% identical to DNA sequences encoding SEQ ID NO:2. SENP1 polynucleotides include, e.g., mRNA encoding

30 SENP1 polypeptides as well as DNA sequences (e.g., cDNA or genomic DNA) encoding SENP1 polypeptides. SENP1 polypeptides will generally be at least 90%, 95% or 99% identical to SEQ ID NO:2.

"**Telomerase**" refers to a ribo-protein complex that maintains the ends of chromosomes (telomeres) or polynucleotides encoding components of the ribo-protein. See, e.g., Shippen-Lentz *et al.*, *Science* 247 (1990) 546; Greiden *et al.*, *Nature* 337 (1989) 331. Telomerase includes two main components: telomerase reverse transcriptase protein (encoded by the gene, *TERT*) and the telomerase RNA component (encoded by the gene, *TERC*). The equivalent human components are known as TERT (e.g., protein sequence: NP\_003210 (SEQ ID NO:3), encoded by, e.g., nucleotide sequence: NM\_003219 (SEQ ID NO:4)) and TERC (NR\_001566 (SEQ ID NO:5)). Splice variants of the RNA encoding TERT are intended to be encompassed by this definition.

"**Contacting a plurality of agents to a cell**" refers to contacting at least two agents to a cell or cells. While multiple agents may be contacted to one cell or pool of cells, the phrase also encompasses contacting a first agent to a first cell or pool of cells and a second agent to a second cell or pool of cells, e.g., such that each cell or pool of cell is contacted by a single agent.

"**Determining the quantity of SENP1 or telomerase**" refers to using any technique known to those of skill in the art to quantify the amount of SENP1 or telomerase polypeptide or polynucleotide (e.g., structural RNA, mRNA or cDNA) or SENP1 or telomerase activity in a sample.

A "**neoplastic phenotype**" refers to the phenotype of a neoplastic cell. Exemplary phenotypes include, e.g., cell growth on soft agar; anchorage independence; reduced contact inhibition and/or density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum independence; accumulation of tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis *in vivo*; mRNA and protein expression patterns of cells undergoing metastasis; and other characteristics of cancer cells.

An "**amplification reaction**" refers to any reaction (e.g., chemical or enzymatic) that results in increased copies of a template nucleic acid sequence or increased signal indicating the presence of the template nucleic acid. "Selective amplification" or "selectively amplifying" refers to amplification of particular sequences in a population of sequences.

- 15 -

The term "**biological sample**" encompasses a variety of sample types obtained from an organism and can be used in a diagnostic or monitoring assay. The term encompasses urine, urine sediment, blood, saliva, and other liquid samples of biological origin, solid tissue samples, such as a biopsy specimen or tissue cultures or cells derived therefrom and the progeny thereof. The term encompasses samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, sedimentation, or enrichment for certain components. The term encompasses a clinical sample, and also includes cells in cell culture, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples.

An "**antagonist**" refers to a molecule which, when contacted to a cell expressing SENP1, inhibits SENP1 activity or expression. Antagonists are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of SENP1.

As used herein, the terms "**nucleic acid**," "**nucleotide**," "**polynucleotide**" and "**oligonucleotide**" refer to primers, probes, oligomer fragments to be detected, oligomer controls and unlabeled blocking oligomers and is generic to polydeoxyribonucleotides (containing 2-deoxy-D-ribose), to polyribonucleotides (containing D-ribose), and to any other N-glycoside of a purine or pyrimidine base, or modified purine or pyrimidine bases.

A nucleic acid, nucleotide, polynucleotide or oligonucleotide can comprise phosphodiester linkages or modified linkages including, but not limited to phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages. The terms encompass peptide-nucleic acids (PNAs) and intercalating nucleic acids (INAs).

A nucleic acid, nucleotide, polynucleotide or oligonucleotide can comprise the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil) and/or bases other than the five biologically occurring bases. These bases may

- 16 -

serve a number of purposes, e.g., to stabilize or destabilize hybridization; to promote or inhibit probe degradation; or as attachment points for detectable moieties or quencher moieties. For example, a polynucleotide of the invention can contain one or more modified, non-standard, or derivatized base moieties, including, but not limited to, N<sup>6</sup>-methyl-adenine, N<sup>6</sup>-tert-butyl-benzyl-adenine, imidazole, substituted imidazoles, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5- oxyacetic acidmethylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, 2,6- diaminopurine, and 5-propynyl pyrimidine. Other examples of modified, non-standard, or dervatized base moities may be found in U.S. Patent Nos. 6,001,611, 5,955,589, 5,844,106, 5,789,562, 5,750,343, 5,728,525, and 5,679,785, each of which is incorporated herein by reference in its entirety.

Furthermore, a nucleic acid, nucleotide, polynucleotide or oligonucleotide can comprise one or more modified sugar moieties including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

It is not intended that the present invention be limited by the source of a nucleic acid, nucleotide, polynucleotide or oligonucleotide. A nucleic acid, nucleotide, polynucleotide or oligonucleotide can be from a human or non-human mammal, or any other organism, or derived from any recombinant source, synthesized in vitro or by chemical synthesis. A nucleic acid, nucleotide, polynucleotide or oligonucleotide may be DNA, RNA, cDNA, DNA-RNA, locked nucleic acid (LNA), peptide nucleic acid (PNA), a hybrid or any mixture of the same, and may

- 17 -

exist in a double-stranded, single-stranded or partially double-stranded form. The nucleic acids of the invention include both nucleic acids and fragments thereof, in purified or unpurified forms, including genes, chromosomes, plasmids, the genomes of biological material such as microorganisms, e.g., bacteria, yeasts, viruses, viroids, molds, fungi, plants, animals, humans, and the like.

5 There is no intended distinction in length between the terms nucleic acid, nucleotide, polynucleotide and oligonucleotide, and these terms will be used interchangeably. These terms include double- and single-stranded DNA, as well as double- and single-stranded RNA. While oligonucleotides may be any length, they may have fewer than 500 nucleotides, e.g., 5-100, 10-100, 10-30, 15-30, or 15-50 nucleotides.

The terms "**polypeptide**," "**peptide**" and "**protein**" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

15 The term "**amino acid**" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline,  $\gamma$ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an  $\alpha$  carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

30 Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB

- 18 -

Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

The phrase “**selectively (or specifically) hybridizes to**” refers to the binding, duplexing, or hybridizing of a molecule predominantly (e.g., at least 50% of the hybridizing molecule) to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA). Polynucleotide primers specifically hybridize to a polynucleotide template in an amplification reaction (e.g., at an annealing temperature of about 60° C) when the primers amplify the template in a reaction mixture comprising a complex mixture of polynucleotides (e.g., isolated from a cell) to produce an amplification product that is at least the most predominant amplification product and is preferably the only significant (e.g., representing at least 90-95% of all amplification products in the sample) amplification product of the reaction.

The phrase “**stringent hybridization conditions**” refers to conditions under which a probe will predominantly hybridize to its target subsequence in a complex mixture of nucleic acids. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also

- 19 -

be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, optionally 10 times background hybridization. Exemplary stringent hybridization conditions can be as follows: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides that they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Exemplary cycle conditions for both high and low stringency amplifications include, but are not limited to, a denaturation phase of about 30 seconds to about 2 minutes at 90°C - 95°C, an annealing phase of about 5 seconds to about 2 minutes at 50°C - 70°C, and an extension phase of about 1 minute to about 5 minutes at about 70°C.

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon,

- 20 -

which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain ( $V_L$ ) and variable heavy chain ( $V_H$ ) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce  $F(ab)'_2$ , a dimer of Fab which itself is a light chain joined to  $V_H$ - $C_{H1}$  by a disulfide bond. The  $F(ab)'_2$  may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the  $F(ab)'_2$  dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (*see Fundamental Immunology* (Paul ed., 3d ed. 1993)). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized *de novo* using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (*see, e.g., McCafferty et al., Nature* 348 (1990) 552-554).

For preparation of monoclonal or polyclonal antibodies, any technique known in the art can be used (*see, e.g., Kohler & Milstein, Nature* 256 (1975) 495-497; Kozbor *et al., Immunology Today* 4 (1983) 72; Cole *et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy* (1985)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab

- 21 -

fragments that specifically bind to selected antigens (*see, e.g., McCafferty et al., Nature* 348 (1990) 552-554; Marks *et al., Biotechnology* 10 (1992) 779-783).

The phrase “**specifically (or selectively) binds**” to an antibody or “**specifically (or selectively) immunoreactive with**,” when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised against SENP1 can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with SENP1 and not with other proteins, except for polymorphic variants and alleles of SENP1. This selection may be achieved by subtracting out antibodies that cross-react with SENP1 molecules from other species or that cross-react with non-SENP1 proteins. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (*see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual* (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

The terms “**identical**” or “**100% identity**,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same sequences. Two sequences are “**substantially identical**” or a certain percent identity if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region, or, when not specified, over the entire sequence*), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual

- 22 -

alignment and visual inspection. The invention provides oligonucleotides that are substantially identical to at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, or more contiguous nucleotides of SENP1 polynucleotides or telomerase polynucleotides or complements thereof.

5 For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can  
10 be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A “**comparison window**”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of  
15 from 5 to 600, usually about 10 to about 100, more usually about 15 to about 50 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local  
20 homology algorithm of Smith and Waterman, *Adv. Appl. Math.* 2 (1970) 482c, by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48 (1970) 443, by the search for similarity method of Pearson and Lipman, *Proc. Nat'l. Acad. Sci. USA* 85 (1988) 2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics  
25 Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Ausubel et al., Current Protocols in Molecular Biology* (1995 supplement)).

Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which  
30 are described in Altschul *et al.*, *Nuc. Acids Res.* 25 (1977) 3389-3402, and Altschul *et al.*, *J. Mol. Biol.* 215 (1990) 403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for

- 23 -

Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length  $W$  in the query sequence, which either match or satisfy some positive-valued threshold score  $T$  when aligned with a word of the same length in a database sequence.  $T$  is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased.

Cumulative scores are calculated using, for nucleotide sequences, the parameters  $M$  (reward score for a pair of matching residues; always  $> 0$ ) and  $N$  (penalty score for mismatching residues; always  $< 0$ ). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity  $X$  from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters  $W$ ,  $T$ , and  $X$  determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength ( $W$ ) of 11, an expectation ( $E$ ) of 10,  $M=5$ ,  $N=-4$  and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation ( $E$ ) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89 (1989) 10915) alignments ( $B$ ) of 50, expectation ( $E$ ) of 10,  $M=5$ ,  $N=-4$ , and a comparison of both strands. Either program is run with the low complexity filter "off".

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.*, Karlin and Altschul, *Proc. Natl. Acad. Sci. USA* 90 (1993) 5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability ( $P(N)$ ), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test

nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

## DETAILED DESCRIPTION OF THE INVENTION

### 5 I. Introduction

Not all tumors of a given cancer type contain detectable levels of telomerase activity. *See, e.g.*, Shay, J.W. and Bacchetti, S. *Eur. J. Cancer*, 33 (1997) 787-791; Yan, P. *et al. Cancer Res.* 59 (1999) 3166-3170. In general, 50-100% of tumors of different types have measurable telomerase activity (Bryan, T.M., *Nature Medicine* 10 3 (1997) 1271-1274; Kim, N.W. *et al. Science* 266 (1994) 2011-2015; Bacchetti, S. and Counter, C.M. *Int. J. Oncology* 7 (1995) 423-432). Thus, while this failure to detect telomerase activity could be due to an inability to measure low levels, it is more likely that expression of telomerase may be sufficient to cause cancer, but it is not necessary. That is, some tumors may not express active telomerase.

15 Indeed it has been found that some immortalized cell lines and tumors are capable of maintaining telomeres without telomerase. *See, e.g.*, Bryan, *et al. Nature Medicine* 3 (1997) 1271-1274; Scheel, C. and Poremba, C. *Virchows Arch* 440 (2002) 573-582; McEachern, M.J., *et al. Annu. Rev. Genet.* 34 (2000) 331-358). This alternative lengthening of telomeres (ALT), at least in some cases, occurs by

20 homologous recombination (Dunham, M.A. *et al., Nature Genetics* 26 (2000) 447-450). Epithelial cells appear to be immortalized by ALT much less frequently than fibroblasts (Bryan, T.M., *et al. Nature Medicine* 3 (1997) 1271-1274); Mehle, C., *et al., Oncogene* 13 (1996) 161-166).

Interestingly, cancers are largely epithelial in origin, which may account for the

25 generally high percentages of tumors which are telomerase positive. However, if telomeres of tumors in some populations of patients are maintained by a telomerase-independent mechanism, this sets the upper limit of obtainable sensitivity for any telomerase-based assay designed to diagnose or monitor recurrence of a cancer. Certain tumors would escape detection using telomerase as

30 the only cancer marker.

The inventors recognized a need for a method of detecting tumors that do not express telomerase. The present invention is based in part on the discovery that

- 25 -

increased expression of SENP1 is a useful marker to identify cancers that do not have detectable telomerase levels. Thus, by detecting both SENP1 and telomerase in a sample, it is possible to detect a significant number of cancers. Accordingly, the present invention provides methods of detecting the presence of cancer cells in a biological sample by determining the quantity of SENP1 and telomerase in the sample.

In addition, the present invention is based in part on the discovery that increased expression of SENP1 is a useful marker to identify cancer, including, e.g., bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, small intestine cancer, and bladder cancer. Moreover, the inventors have shown that the use of both SENP1 and telomerase as markers can allow for greater sensitivity and specificity for detecting selected cancers rather than use of either marker alone. Accordingly, the present invention provides methods of detecting the presence of cancer cells in a biological sample by determining the quantity of SENP1 and, optionally telomerase, in the sample. Thus, in some embodiments of the invention, both SENP1 and telomerase are detected, wherein an increase in either marker indicates the presence of, e.g., bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, small intestine cancer, or bladder cancer.

This invention relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (3rd ed. 2001); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 2002).

25

## ***II. Detection and Quantification of SENP1 and/or Telomerase***

The present invention provides for any methods of quantifying SENP1 and/or telomerase polynucleotides (including SENP1 mRNA, SENP1 cDNA, TERT mRNA, TERT cDNA, TERC RNA, TERC cDNA, etc.) and/or SENP1 and/or telomerase polypeptides and/or the activity of SENP1 and/or telomerase known to those of skill in the art either sequentially or simultaneously in one or multiple assays. Exemplary approaches for detecting SENP1 or telomerase detection

30

- 26 -

include, e.g., (a) detection of SENP1 or telomerase polynucleotides, including using polynucleotide hybridization and/or amplification reaction-based assays; (b) detection of SENP1 or telomerase proteins, including using affinity agent-based assays involving an agent that specifically binds to a SENP1 or telomerase polypeptide or polynucleotide; and/or (c) detection of SENP1 or telomerase activity. All of these methods allow for subsequent direct or indirect quantification of the detected targets, i.e., SENP1 and telomerase.

Typically, the cancer-associated SENP1 polynucleotides or polypeptides detected herein will be at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:1 or to those polynucleotides encoding SEQ ID NO:2 or to one or more of the SENP1 sequences available, e.g., from GenBank (*see, e.g.*, SENP mRNA sequence at NM\_014554 and the SENP1 polypeptide at NP\_055369). Similarly, telomerase polynucleotides (e.g., *TERT* RNA or *TERC*) or polypeptides (e.g., *TERT*) detected herein will be at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to a telomerase polynucleotide or polypeptide. The detected SENP or telomerase polynucleotides or polypeptides can represent functional or nonfunctional forms of the cancer-associated polynucleotide or polypeptide, or any variant, derivative, or fragment thereof. Typically, the level and/or presence of cancer-associated polynucleotides or polypeptides in a biological sample will be detected.

Methods of detecting telomerase expression may include the same type methods as used for detecting SENP1 (e.g., both telomerase and SENP1 polynucleotides are detected) or different methods (e.g., SENP1 polynucleotides and telomerase activity are detected). However, for user convenience, it can be desirable to use the same detection assay for both telomerase and SENP1. For example, in some embodiments, quantitative multiplex reverse transcription-polymerase chain reaction (RT-PCR) reactions can be used to quantify both SENP1 and telomerase expression in a sample. In some embodiments, real-time quantitative RT-PCR is performed.

30

### A. *Detection of mRNA Expression*

Detection assays may be carried out on preparations containing mRNA or cDNA generated from isolated mRNA in a manner that reflects the relative levels of mRNA transcripts in the sample. Methods of detecting telomerase RNA have been described and can generally be adapted for detecting SENP1. *See, e.g.*, U.S. Patent Nos. 6,582,964; 5,846,723; 6,607,898; U.S. Patent Publication No. 2002/0012969; and Angelopoulou *et al.*, *Anticancer Res.* 23 (2003) 4821-4829.

#### 1. *Amplification-based Assays*

##### a. *Detection methods*

In some embodiments, levels of RNA can be determined using amplification reactions, such as PCR. For example, using one or more oligonucleotide primers can be used to amplify a region of a SENP1 polynucleotide (e.g., a SENP1 or telomerase cDNA). Amplification reactions useful for the present invention include, but are not limited to, polymerase chain reaction (PCR) and ligase chain reaction (LCR) (*see* U.S. Pat. Nos. 4,683,195 and 4,683,202; *PCR Protocols. A Guide to Methods and Applications* (Innis *et al.*, ed., (1990)), strand displacement amplification (SDA) (Walker, *et al. Nucleic Acids Res.* 20 (1992) 1691-1696; Walker, *PCR Methods Appl* 3 (1993) 1-6), transcription-mediated amplification (Phyffer, *et al.*, *J. Clin. Microbiol.* 34 (1996) 834-841; Vuorinen, *et al.*, *J. Clin. Microbiol.* 33 (1995) 1856-1859), nucleic acid sequence-based amplification (NASBA) (Compton, *Nature* 350 (1991) 91-92), rolling circle amplification (RCA) (Lisby, *Mol. Biotechnol.* 12 (1999) 75-99); Hatch *et al.*, *Genet. Anal.* 15 (1999) 35-40) branched DNA signal amplification (bDNA) (*see, e.g.*, Iqbal *et al.*, *Mol. Cell Probes* 13 (1999) 315-320) and Q-Beta Replicase (Lizardi *et al.*, *Bio/Technology* 6 (1988) 1197).

Although any type of amplification reaction can be used, in some embodiments, PCR is used to amplify DNA templates. The PCR primers will typically be designed to specifically hybridize to the SENP1 polynucleotide, e.g., under conditions used in a PCR reaction. For example, primers typically hybridize in standard PCR buffers (such as, but not limited to, those containing 50 mM bicine, pH 8.0, 115 mM potassium acetate, 8% glycerol, 3 mM manganese acetate, 200

- 28 -

uM each deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate, and 500 uM of deoxyuridine triphosphate, 2 Units of uracil N-glycosylase (UNG), 10 Units of DNA polymerase, 200 nM each primer, forward and reverse, and optionally a polynucleotide probe) at about 60° C. Generally, primers are designed and/or tested to avoid significant homology or hybridization to other polynucleotides likely to be found in the biological sample (e.g., in the human genome). Alternative methods of amplification (e.g., LCR, SDA, RCA, Q-Beta, etc.) have been described and can also be employed.

In some embodiments, SENP1 or telomerase RNA can be detected using reverse transcriptase polymerase chain reaction (RT-PCR). RT-PCR methods are well known to those of skill (see, e.g., *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 2002)).

Amplification methods employed to detect SENP1 polynucleotides may involve a quantitative PCR methodology such as, for example, the real-time PCR, including  
5 quantitative RT-PCR. Methods of quantitative amplification are disclosed in, e.g., U.S. Patent Nos. 6,180,349; 6,033,854; and 5,972,602, as well as in, e.g., Gibson *et al.*, *Genome Research* 6 (1996) 995-1001; DeGraves, *et al.*, *Biotechniques* 34 (2003) 106-110, 112-115; Deiman B. *et al.*, *Mol Biotechnol.* 20 (2002) 163-179).

To quantify the amount of specific RNA in a sample, a standard curve may be  
20 generated from run-off transcription of a plasmid containing the gene of interest. Standard curves may be generated using the threshold values (Ct) values determined in the real-time PCR, which are related to the initial cDNA concentration used in the assay. In addition, a standard curve may be generated for a standard polynucleotide (e.g., a previously quantified sequence). This permits  
25 standardization of initial RNA content of a biological sample to the amount of standard for comparison purposes. See, e.g., *The PCR Technique: Quantitative PCR*, J. Larrick (ed.) 1997).

One method for detection of amplification products is the 5' nuclease PCR assay (using e.g., COBAS TaqMan 48 Analyzer™ (Roche Molecular Systems,  
30 Pleasanton, CA)). See, e.g., Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88 (1991) 7276-7280; Lee *et al.*, *Nucleic Acids Res.* 21 (1993) 3761-3766; U.S. Patent Nos. 6,214,979; 5,804,375; 5,487,972; and 5,210,015. This assay detects the

- 29 -

accumulation of a specific PCR product by hybridization and cleavage of a doubly labeled fluorogenic probe during the amplification reaction. The fluorogenic probe may consist of an oligonucleotide (e.g., that hybridizes to a SENP1 or telomerase polynucleotide or its complement) labeled with both a fluorescent reporter dye and a quencher dye. During PCR, this probe is cleaved by the 5'-nuclease activity of DNA polymerase if, and only if, it hybridizes to the segment being amplified. Cleavage of the probe generates an increase in the fluorescence intensity of the reporter dye.

In some embodiments, the enzymes with 5' nuclease activity are thermostable and thermoactive nucleic acid polymerases. Such thermostable polymerases include, but are not limited to, native and recombinant forms of polymerases from a variety of species of the eubacterial genera *Thermus*, *Thermatoga*, and *Thermosipho*. For example, *Thermus* species polymerases that can be used in the methods of the invention include *Thermus aquaticus* (*Taq*) DNA polymerase, *Thermus thermophilus* (*Tth*) DNA polymerase, *Thermus* species Z05 (*Z05*) DNA polymerase, *Thermatoga maritima* DNA polymerase, *Thermatoga neapolitana* DNA polymerase and *Thermus* species sps17 (*sps17*), as described in U.S. Pat. Nos. 5,405,774, 5,352,600, 5,079,352, 4,889,818, 5,466,591, 5,618,711, 5,674,738, and 5,795,762.

Another method of detecting amplification products that relies on the use of energy transfer is the "molecular beacon probe" method described by Tyagi and Kramer (*Nature Biotech.* 14 (1996) 303-309), which is also the subject of U.S. Pat. Nos. 5,119,801 and 5,312,728. This method employs oligonucleotide hybridization probes that can form hairpin structures. On one end of the hybridization probe (either the 5' or 3' end), there is a donor fluorophore, and on the other end, an acceptor moiety. In the case of the Tyagi and Kramer method, this acceptor moiety is a quencher, that is, the acceptor absorbs energy released by the donor, but then does not itself fluoresce. Thus, when the beacon is in the open conformation, the fluorescence of the donor fluorophore is detectable, whereas when the beacon is in hairpin (closed) conformation, the fluorescence of the donor fluorophore is quenched. When employed in PCR, the molecular beacon probe, which hybridizes to one of the strands of the PCR product, is in "open conformation," and

- 30 -

fluorescence is detected, while those that remain unhybridized will not fluoresce (Tyagi and Kramer, *Nature Biotechnol.* 14 (1996) 303-306. As a result, the amount of fluorescence will increase as the amount of PCR product increases, and thus may be used as a measure of the progress of the PCR. Those of skill in the art will recognize that other methods of quantitative amplification are also available. Other types of probes useful for real time PCR methods include Scorpion™ probes, which are available in "uni-labeled" and "bi-labeled" formats from Prologo, C (Boulder, CO). *See, also*, Bates *et al.*, *Mol. Plant Pathol.* 2 (2001) 275-280.

In still another example, two primers and a probe of the invention may be used to detect and quantify a target nucleic acid using nucleic acid sequence-based amplification (NASBA). In some NASBA methods, three enzymes are used, including reverse transcriptase, T7 RNA polymerase, and RNase H. The final amplification product is single-stranded RNA with a polarity opposite that of the nucleic acid to be detected. The amplified RNA product can be detected in some embodiments through the use of a target-specific capture probe bound to magnetic particles in conjunction with a ruthenium-labeled detector probe and an instrument (NucliSens Reader; bioMérieux) capable of measuring electrochemiluminescence (ECL). Alternatively, RNA amplified by NASBA can specifically be detected in real time by including molecular beacon probes in the amplification reaction, as described above. Further guidance on use of the primers and probes of the invention may be found in articles by Compton, *Nature* 350 (1991) 91-92 and Kievits *et al.*, *J. Virol. Methods* 35 (1991) 273-286.

Another example of methods that use a nucleic acid primer and a probe to detect and quantify a target nucleic acid involves the use of nanoparticles. In such methods, two oligonucleotides, such as a primer or probe of the invention, that can hybridize to different regions of a nucleic acid to be detected are covalently linked to a nanoparticle. The nanoparticles are contacted with a target nucleic acid under hybridization conditions. If the nucleic acid is present, the nucleic acid will bind to the oligonucleotides attached to the nanoparticles, producing a large molecular weight complex that can be detected. The complex can be detected by any method known to one of skill in the art without limitation. In certain embodiments, the complex is detected by precipitation of the complex. Further guidance on methods

- 31 -

of using nanoparticles in connection with the primers and probes of the invention may be found in Taton *et al.*, *Science* 289(2000) 1757-1760 and U.S. Patent Nos. 6,506,564, 6,495,324, 6,417,340, 6,399,303, and 6,361,944.

5 In yet another example, rolling circle amplification (“RCA”) can be used as part of a method for detecting and quantifying a target nucleic acid. In certain embodiments of RCA methods, a DNA circle is amplified by polymerase extension of a complementary primer. Any of the primers or probes of the invention can be used in such methods. Methods of circularizing DNA are well known in the art, and include, for example, ligating the ends of a DNA molecule together under  
10 conditions which favor intramolecular ligation. The single-stranded product concatamer product can then be detected by any method of detecting a nucleic acid known to one of skill in the art without limitation. For example, the concatamer product can be detected using a detectably-labeled probe of the invention. Other examples of methods of detecting a nucleic acid of known sequence are extensively  
15 described herein. In other embodiments of RCA, a second primer can be used that is complementary to the concatamer product. This primer allows exponential amplification of the sequences present in the circular DNA template. The products of the amplification can still be detected, for example, by using a detectably-labeled probe of the invention. Further guidance on using the primers and probes of the  
20 invention in RCA methods for detecting a target nucleic acid may be found in U.S. Patent Nos. 6,344,329, 6,350,580, 6,221,603, 6,210,884, 5,648,245, and 5,714,320 and WO95/35390.

In another example of such methods, a target nucleic acid can be detected and  
25 quantified using Strand Displacement Amplification (“SDA”). In such methods, amplified nucleic acids are detected by incorporation of a single-stranded primer that comprises a fluorescent moiety, a quencher moiety, and an engineered restriction site separating the two moieties. One of skill in the art can easily recognize how to modify any of the primers or probes of the invention for use in SDA.

30 In a first amplification reaction used in SDA, the primer is used to amplify a target nucleic acid in the presence of, for example, thio-dCTP, thereby incorporating the primer into the amplification product. Then, a restriction endonuclease can be used

- 32 -

to nick the restriction site in the primer. The restriction endonuclease cannot cut both strands of the amplification product because of the incorporation of thio-dCTP in the amplification product. Finally, the 3' end of the primer created by the nick can be used to prime a new polymerization reaction, thereby displacing the portion of the strand 3' to the nick from the template strand. Displacement of the strand separates the fluorescent moiety from the quencher moiety, thereby preventing quenching of fluorescence emitted by the fluorescent moiety. A SENP1 or telomerase polynucleotide can thereby be detected and/or quantified by measuring the presence and/or amount of fluorescence. Further guidance on selection and modification of primers and probes for use in SDA may be found in Little *et al.*, *Clin. Chem.* 45 (1999) 777-784, and U.S. Patent Nos. 6,528,254 and 6,528,632. In another example, a SENP1 or telomerase polynucleotide may be detected and quantified using transcription-mediated amplification ("TMA"). TMA is an RNA transcription amplification system that uses RNA polymerase and reverse transcriptase to amplify the nucleic acids to be detected. In the method, a primer of the invention with a promoter for RNA polymerase is used to prime reverse transcription of a target RNA. The RNase activity of reverse transcriptase then degrades the RNA template, releasing the cDNA strand. Second strand synthesis is primed with a second primer of the invention and catalyzed by reverse transcriptase. RNA polymerase then recognizes the promoter synthesized in the second strand and catalyzes multiple cycles of RNA transcription from the second strand. The RNA product can then be detected or can serve as template for another round of amplification.

The RNA product of TMA can then be detected and quantified by any method known to one of skill in the art. In certain embodiments, the RNA product can be detected with a probe of the invention. In other embodiments, the RNA product can be detected with a probe of the invention that has been labeled with an acridine-ester label (Gen-Probe, Inc., San Diego, CA). Such labels can be chemically removed from unhybridized probe while labels on hybridized probes remain undisturbed. Thus, in such embodiments, presence of a target nucleic acid can be detected by detecting the presence of the acridine-ester label. Further guidance in using the primers and probes of the invention in TMA-based methods

- 33 -

may be found in Arnold *et al.*, *Clin. Chem.* 35 (1989) 1588-1594; Miller *et al.*, *J. Clin. Microbiol.* 32 (1994) 393-397; and U.S. Patent Nos. 6,335,166 and 6,294,338. In other embodiments, any assay known by one of skill in the art that uses a single nucleic acid primer or probe that can hybridize to a nucleic acid to detect the

5 nucleic acid can be used to detect a SENP1 or telomerase polynucleotide. For example, a SENP1 or telomerase polynucleotide can be detected using a primer to initiate a primer extension reaction. Successful extension of the primer by a nucleic acid polymerase indicates the presence of the SENP1 or telomerase polynucleotide. Other examples of single primer or probe detection methods that

10 describe methods that can be used as described or adapted by one of skill in the art to detect a SENP1 or telomerase polynucleotide can be found in U.S. Patent Nos. 6,440,707, 6,379,888, 6,368,803, 6,365,724, 6,361,944, 6,352,827, 6,326,145, 6,312,906, 6,268,128, 6,261,784, 6,177,249, 6,140,055, 6,130,047, 6,124,090, 6,121,001, 6,110,677, 6,054,279, 6,022,686, 5,981,176, 5,958,700, 5,945,283,

15 5,935,791, 5,919,630, 5,888,739, 5,888,723, 5,882,867, 5,876,924, 5,866,336, 5,856,092, 5,853,990, 5,846,726, 5,814,447, 5,808,036, 5,800,989, 5,795,718, 5,792,614, 5,710,028, 5,683,875, 5,683,872, 5,679,510, 5,641,633, 5,597,696, 5,595,890, 5,571,673, 5,547,861, 5,525,462, 5,514,546, 5,491,063, 5,437,977, 5,294,534, 5,118,605, 5,102,784, 4,994,373, 4,851,331, 4,767,700.

20

**b. Primers of the invention**

Exemplary oligonucleotide primers may comprise a sequence at least 70%, 75%, 80%, 85%, 90%, 95% or 100% identical to at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, or other number of contiguous

25 nucleotides of SENP1 polynucleotides or telomerase (e.g., TERC or TERT) polynucleotides or complements thereof.

The length and composition of the probe can be chosen to give sufficient thermodynamic stability to ensure hybridization of the probe to the template nucleic acid under the appropriate reaction conditions, which depend on the

30 detection method to be performed. For example, probes with modified, non-standard, or derivatized nucleotides may be longer or shorter than those with conventional nucleotides while having similar thermodynamic hybridization

- 34 -

properties. Examples of such non-standard bases may be found in U.S. Patent Nos. 6,320,005, 6,174,998, 6,001,611, and 5,990,303. As another example, probes with G/C-rich sequences may anneal to target sequences at higher temperatures than a probe of similar length with A/T-rich sequences.

5

*c. Probes of the invention*

Exemplary detectably-labeled oligonucleotide probes may comprise a sequence at least 70%, 75%, 80%, 85%, 90%, 95% or 100% identical to at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, or other number of contiguous nucleotides of SENP1 polynucleotides or telomerase (e.g., TERC or TERT) polynucleotides or complements thereof.

In addition to the probe nucleotide sequence as described herein, the probe can comprise additional nucleotide sequences or other moieties that do not inhibit the methods of the instant invention. In some embodiments of the invention, the probe can comprise additional nucleotide sequences or other moieties that facilitate the methods of the instant invention. For instance, the probe can be blocked at its 3' terminus to prevent undesired nucleic acid polymerization priming by the probe. Also, moieties may be present within the probe that stabilize or destabilize hybridization of the probe or probe fragments with the nucleotide sequence. The probes of the invention can also comprise modified, non-standard, or derivatized nucleotides as defined above.

In certain embodiments of the invention, the probe can comprise a detectable moiety. The detectable moiety can be any detectable moiety known by one of skill in the art without limitation. Further, the detectable moiety can be detectable by any means known to one of skill in the art without limitation. For example, the detectable moiety can be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means.

A variety of detectable moieties that can be used to detect the probes of the invention, as well as methods for their linkage to the probe, are known to the art and include, but are not limited to, enzymes (e.g., alkaline phosphatase and horseradish peroxidase) and enzyme substrates, radioactive moieties, fluorescent moieties, chromophores, chemiluminescent labels, electrochemiluminescent labels,

30

- 35 -

such as Origin™ (Igen, Rockville, MD), ligands having specific binding partners, or any other labels that may interact with each other to enhance, alter, or diminish a signal. Of course, if a 5' nuclease reaction is performed using a thermostable DNA polymerase at elevated temperatures, in some embodiments, the detectable moiety is not degraded or otherwise rendered undetectable by such elevated temperatures. In certain embodiments, the detectable moiety can be a fluorescent moiety. The fluorescent moiety can be any fluorescent moiety known to one of skill in the art without limitation. In some embodiments, fluorescent moieties with wide Stokes shifts are used, allowing for the use of fluorometers with filters rather than monochromometers and increasing the efficiency of detection. In certain embodiments, the fluorescent moiety can be selected from the group consisting of fluorescein-family dyes (Integrated DNA Technologies, Inc., Coralville, IA), polyhalofluorescein-family dyes, hexachlorofluorescein-family dyes, coumarin-family dyes (Molecular Probes, Inc., Eugene, Or), rhodamine-family dyes (Integrated DNA Technologies, Inc.), cyanine-family dyes, oxazine-family dyes, thiazine-family dyes, squaraine-family dyes, chelated lanthanide-family dyes, and BODIPY®-family dyes (Molecular Probes, Inc.). In some embodiments, the fluorescent moiety is 6-carboxyfluorescein (FAM™)(Integrated DNA Technologies, Inc.). Other examples of fluorescent moieties that can be used in the probes, methods, and kits of the invention can be found in U.S. Patent Nos. 6,406,297, 6,221,604, 5,994,063, 5,808,044, 5,880,287, 5,556,959, and 5,135,717. In other embodiments, the detectable moiety can be a detectable moiety other than a fluorescent moiety. Among radioactive moieties, <sup>32</sup>P-labeled compounds are preferred. Any method known to one of skill in the art without limitation may be used to introduce <sup>32</sup>P into a probe. For example, a probe may be labeled with <sup>32</sup>P by 5' labeling with a kinase or by random insertion by nick translation. Detectable moieties that are enzymes can typically be detected by their activity. For example, alkaline phosphatase can be detected by measuring fluorescence produced by action of the enzyme on appropriate substrate compounds. Where a member of specific binding partners is used as detectable moieties, the presence of the probe can be detected by detecting the specific binding of a molecule to the member of the specific binding partner. For example, an antigen can be linked to the probe,

- 36 -

and a monoclonal antibody specific for that antigen can be used to detect the presence of the antigen and therefore the probe. Other specific binding partners that can be used as detectable moieties include biotin and avidin or streptavidin, IgG and protein A, and numerous other receptor-ligand couples well-known to the art. Still other examples of detectable moieties that are not fluorescent moieties can be found in U.S. Patent Nos. 5,525,465, 5,464,746, 5,424,414, and 4,948,882.

The above description of detectable moieties is not meant to categorize the various labels into distinct classes, as the same label may serve in several different modes. For example,  $^{125}\text{I}$  may serve as a radioactive moiety or as an electron-dense reagent. Horseradish peroxidase may serve as enzyme or as antigen for a monoclonal antibody. Further, one may combine various detectable moieties for desired effect. For example, one might label a probe with biotin, and detect its presence with avidin labeled with  $^{125}\text{I}$ , or with an anti-biotin monoclonal antibody labeled with horseradish peroxidase. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.

The method of linking or conjugating the detectable moiety to the probe depends, of course, on the type of detectable moiety or moieties used and the position of the detectable moiety on the probe.

The detectable moiety may be attached to the probe directly or indirectly by a variety of techniques. Depending on the precise type of detectable moiety used, the detectable moiety can be located at the 5' or 3' end of the probe, located internally in the probe's nucleotide sequence, or attached to spacer arms of various sizes and compositions to facilitate signal interactions. Using commercially available phosphoramidite reagents, one can produce oligonucleotides containing functional groups (e.g., thiols or primary amines) at either terminus via an appropriately protected phosphoramidite, and can attach a detectable moiety thereto using protocols described in, for example, Innis et al. (eds.), *PCR Protocols: A Guide to Methods and Applications*, 1990).

Methods for introducing oligonucleotide functionalizing reagents to introduce one or more sulfhydryl, amino or hydroxyl moieties into the oligonucleotide probe sequence, typically at the 5' terminus are described in U.S. Pat. No. 4,914,210. A

- 37 -

5' phosphate group can be introduced as a radioisotope by using polynucleotide kinase and [ $\gamma$ -<sup>32</sup>P]ATP to provide a reporter group. Biotin can be added to the 5' end by reacting an aminothymidine residue or alkylamino linker, introduced during synthesis, with an N-hydroxysuccinimide ester of biotin. Other methods of attaching a detectable moiety, including a fluorescent moiety, to the probe can be found in U.S. Patent No. 5,118,802.

It is also possible to attach a detectable moiety at the 3' terminus of the probe by employing, for example, polynucleotide terminal transferase to add a desired moiety, such as, for example, cordycepin <sup>35</sup>S-dATP, and biotinylated dUTP.

10 Oligonucleotide derivatives are also detectable moieties that can be used in the probes, methods and kits of the present invention. For example, etheno-dA and etheno-A are known fluorescent adenine nucleotides which can be incorporated into an oligonucleotide probe. Similarly, etheno-dC is another analog that could be used in probe synthesis. The probes containing such nucleotide derivatives can be degraded to release mononucleotides that are much more strongly fluorescent than the intact probe by, for example, a polymerase's 5' to 3' nuclease activity.

15 In certain embodiments of the invention, a probe can be labeled with more than one detectable moiety. In certain of such embodiments, each detectable moiety can be individually attached to different bases of the probe. In other embodiments, more than one detectable moiety can be attached to the same base of the probe.

20 In certain embodiments, the detectable moiety can be attached to the 5' end of the probe. In other embodiments, the detectable moiety can be attached to the probe at a residue that is within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, about 35, about 40 residues or other number of residues from the 5' end of the probe. The detectable moiety can be attached to any portion of a residue of the probe. For example, the detectable moiety can be attached to a sugar, phosphate, or base moiety of a nucleotide in the probe. In other embodiments, the detectable moiety can be attached between two residues of the probe.

25 In certain embodiments of the invention, the probe can comprise a fluorescent moiety and a quencher moiety. In such embodiments, the fluorescent moiety can be any fluorescent moiety known to one of skill in the art, as described above.

- 38 -

Further, the quencher moiety can be any quencher moiety known to one of skill in the art without limitation. In certain embodiments, the quencher moiety can be selected from the group consisting of fluorescein-family dyes, polyhalofluorescein-family dyes, hexachlorofluorescein-family dyes, coumarin-family dyes, rhodamine-family dyes, cyanine-family dyes, oxazine-family dyes, thiazine-family dyes, squaraine-family dyes, chelated lanthanide-family dyes, BODIPY®-family dyes, and non-fluorescent quencher moieties. In certain embodiments, the non-fluorescent quencher moieties can be BHQ™-family dyes, Iowa Black™, or Dabcyl (Integrated DNA Technologies, Inc.). Other examples of specific quencher moieties include, for example, but not by way of limitation, TAMRA (N,N,N',N'-tetramethyl-6-carboxyrhodamine) (Molecular Probes, Inc.), DABCYL (4-(4'-dimehtylaminophenylazo)benzoic acid), Iowa Black™ (Integrated DNA Technologies, Inc.), Cy3™ (Integrated DNA Technologies, Inc.) or Cy5™ (Integrated DNA Technologies, Inc.). In a preferred embodiment, the quencher moiety is Cy5™. Other examples of quencher moieties that can be used in the probes, methods, and kits of the invention can be found in U.S. Patent Nos. 6,399,392, 6,348,596, 6,080,068, and 5,707,813, each of which is hereby incorporated by reference in its entirety.

In certain embodiments, the quencher moiety can be attached to the 3' end of the probe. In other embodiments, the quencher moiety can be attached to the probe at a residue that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, about 35, about 40 or other number of residues from the 5' end of the probe. In a preferred embodiment, the fluorescent moiety is attached to the 5' end of the probe and the quencher moiety is attached to a residue that is within about 9 residues of the 5' end of the probe. The quencher moiety can be attached to any portion of a residue of the probe. For example, the quencher moiety can be attached to a sugar, phosphate, or base moiety of a nucleotide in the probe. In other embodiments, the quencher moiety can be attached between two residues of the probe.

While not intending to be bound to any particular theory or mechanism of action, it is believed that when the probe is intact, a photon emitted by the fluorescent moiety can be absorbed and thus quenched by the quencher moiety. The quencher moiety

then either releases the energy of the photon as a photon of different wavelength or as heat. Thus, the quencher moiety can also be a fluorescent moiety. As described above, this phenomenon is termed fluorescence resonance energy transfer ("FRET"). Cleaving the probe between the fluorescent moiety and quencher results in a reduction in quenching of the fluorescent moiety's emitted fluorescence by the quencher moiety.

Generally, transfer of energy between the fluorescent moiety and the quencher moiety depends on the distance between the fluorescent moiety and the quencher moiety and the critical transfer distance of the particular fluorescent moiety-quencher moiety pair. The critical transfer distance is both characteristic and constant for a given fluorescent moiety paired with a given quencher moiety. Further, the spatial relationship of the fluorescent moiety in reference to the quencher moiety can be more sensitively determined when the critical transfer distance of the fluorescent moiety-quencher moiety pair is close to the distance between the fluorescent moiety and the quencher moiety. Accordingly, the skilled practitioner can select the fluorescent moiety and the quencher moiety to have a critical transfer distance that is close to the distance separating the fluorescent moiety from the quencher moiety on the probe. Critical transfer distances of particular fluorescent moiety-quencher moiety pairs are well known in the art and can be found, for example, in an article by Wu and Brand, *Anal. Biochem.* 218 (1994) 1-13.

Other criteria for selection of particular fluorescent moiety-quencher moiety pairs include, for example, the quantum yield of fluorescent emission by the fluorescent moiety; the wavelength of fluorescence emitted by the fluorescent moiety; the extinction coefficient of the quencher moiety; the wavelength of fluorescence, if any, emitted by the quencher moiety; and the quantum yield of fluorescent emission, if any, by the quencher moiety. In addition, if the quencher moiety is also a fluorescent moiety, the quencher moiety and the fluorescent moiety can be selected so that fluorescence emitted by one can easily be distinguished from fluorescence emitted by the other. Further guidance on the selection of particular fluorescent moiety-quencher moiety pairs may be found in a review article by Klostermeier and Millar, *Biopolymers* 61 (2002) 159-179.

- 40 -

Exemplary combinations of fluorescent moieties and quencher moieties that can be used in this aspect of the invention include, but are not limited to the fluorescent moiety rhodamine 590 and the quencher moiety crystal violet. A preferred combination of fluorescent and quencher moieties is the fluorescent moiety 6-carboxyfluorescein and the quencher moiety Cy5™. Other examples of fluorescent moiety-quencher moiety pairs that can be used in the probes, methods, and kits of the invention can be found in U.S. Patent No. 6,245,514.

5  
10  
15  
20  
25  
30

Examples of molecules that can be used as both fluorescent or quencher moieties in FRET include fluorescein, 6-carboxyfluorescein, 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein, rhodamine, 6-carboxyrhodamine, 6-carboxy-X-rhodamine, and 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS). Whether a fluorescent moiety is a donor or an acceptor is defined by its excitation and emission spectra, and the fluorescent moiety with which it is paired. For example, FAM™ is most efficiently excited by light with a wavelength of 488 nm, and emits light with a spectrum of 500 to 650 nm, and an emission maximum of 525 nm. Accordingly, FAM™ is a suitable fluorescent moiety for use with, for example, with TAMRA as quencher moiety, which has at its excitation maximum 514 nm.

## 2. *Hybridization-Based Assays*

20  
25  
30

Methods of detecting and/or quantifying the level of SENP1 or telomerase polynucleotides (RNA or cDNA made therefrom) using nucleic acid hybridization techniques are known to those of skill in the art (*see*, Sambrook *et al.*, (1989) *Molecular Cloning: A Laboratory Manual*, 2d Ed., vols 1-3, Cold Spring Harbor Press, New York). Biological samples can be screened using a SENP1 or telomerase-specific probe. Such probes correspond in sequence to a region of the SENP1 or telomerase RNA, or their complement. Under defined conditions, specific hybridization of such a probe to test nucleic acid is indicative of the presence of the SENP1 or telomerase polynucleotide in a sample. Defined conditions will be sufficient to allow for hybridization of the probe to its target without significantly hybridizing to other polynucleotides in a complex mixture (e.g. genomic DNA from a cell). If desired, more than one probe may be used on the same test sample. The probe may comprise as few as 8, 15, 20, 50 or 100 or

- 41 -

other number of nucleotides of the SENP1 or telomerase RNA sequence or its complement or may comprise as many as 500, 1 kb or the entire RNA sequence or its complement. In some embodiments, the probe is between 12 and 100 nucleotides, or 16-50 nucleotides or 18-40 nucleotides long.

5 One method for evaluating the presence, absence, and/or quantity of SENP1 or telomerase polynucleotides involves a Northern blot: mRNA is isolated from a given biological sample, separated by electrophoresis and transferred from the gel to a solid support (e.g., a nitrocellulose membrane). Labeled SENP1 or telomerase probes are then hybridized to the membrane to identify and/or quantify the mRNA.

10 Expression of SENP1 or telomerase polynucleotides can also be analyzed by other techniques known in the art, e.g., dot blotting, *in situ* hybridization, RNase protection, probing DNA microchip arrays, and the like.

An alternate method that is quite useful when large numbers of different probes are to be used is a "reverse" dot blot format, in which the amplified sequence contains

15 a label, and the probe is bound to the solid support. This format would be useful if the assay methods of the present invention were used as one of a battery of methods to be performed simultaneously on a sample. In this format, the unlabeled probes are bound to the membrane and exposed to the labeled sample under

20 appropriately stringent hybridization conditions. Unhybridized labeled sample is then removed by washing under suitably stringent conditions, and the filter is then monitored for the presence of bound sequences.

Both the forward and reverse dot blot assays can be carried out conveniently in a microtiter plate; *see* U.S. Patent Application No. 07/695,072 and U.S. Patent No. 5,232,829. The probes can be attached to bovine serum albumin (BSA), for

25 example, which adheres to the microliter plate, thereby immobilizing the probe.

Another example of a method of using a probe of the invention to detect a SENP1 or telomerase polynucleotide is described in U.S. Patent No. 6,383,756, which provides a method for detecting a nucleic acid bound to a membrane.

In another example, a SENP1 or telomerase polynucleotide can be detected using

30 branched-DNA-based methods. In such methods, a dendrimer monomer is constructed of two DNA strands that share a region of sequence complementarity located in the central portion of each strand. When the two strands anneal to form

- 42 -

the monomer the resulting structure has a central double-stranded center bordered by four single-stranded ends. A dendrimer can be assembled from monomers by hybridization of the single stranded ends of the monomers to each other, while still leaving many single-stranded ends free. These free single-stranded ends can have the sequences of any of the primers or probes of the invention. A dendrimer can be detectably-labeled with any detectable moiety known to one of skill in the art without limitation, as described above in connection with the probes of the invention.

Dendrimers can then be used as a probe, in, for example, the "dot blot" assays described below. In addition, a dendrimer can be used as a probe in any method known to one of skill in the art in which the probe is directly detected. A probe is directly detected when the presence of the probe can be determined without any subsequent reaction or modification, such as a dot blot or Southern hybridization. Further guidance on the selection and use of dendrimers as probes may be found in U.S. Patent Nos. 6,261,779 and in Nilsen *et al.*, *J. Theoretical Biology* 187 (1997) 273-284; Capaldi *et al.*, *Nucleic. Acids Res.*, 28 (2000) 21e; Wang *et al.*, *J. Am. Chem. Soc.* 120 (1998) 8281-8282; and Wang *et al.*, *Electroanalysis* 10 (1998) 553-556.

### **B. Detection of SENP1 DNA**

In some cases, it will be advantageous to detect and analyze genomic DNA encoding SENP1. For example, it can be useful to determine the structure and/or nucleotide sequence of a genomic sequence encoding SENP1 or comprising SENP1 regulatory sequences to identify mutations associated with cancer or other diseases. Similarly, SENP1 cDNA sequences can be analyzed and/or nucleotide sequenced.

In some cases, SENP1 genomic sequences are analyzed to identify polymorphisms (e.g., variants) between commonly occurring alleles and alleles associated with cancer. Types of molecular analyses include, but are not limited to: RFLP analysis, PCR-based analyses, SNP analyses, etc.

- 43 -

**C. Detection and quantification of SENP1 or telomerase polypeptides**

In addition to the detection of SENP1 or telomerase polynucleotides, one can also use affinity assays such as immunoassays to detect SENP1 or telomerase polypeptides. Immunoassays will typically be used to quantify SENP1 or telomerase polypeptides in a sample. A general overview of the applicable technology can be found in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988).

Methods of producing polyclonal and monoclonal antibodies that react specifically with SENP1 or telomerase polypeptides are known to those of skill in the art (*see, e.g.,* Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *supra*; Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986); and Kohler and Milstein, *Nature* 256 (1975) 495-497. Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (*see, e.g.,* Huse *et al.*, *Science* 246 (1989) 1275-1281; Ward *et al.*, *Nature* 341 (198) 544-546).

SENP1 and/or telomerase polypeptides may be used to produce antibodies specifically reactive with SENP1 or telomerase, respectively. For example, a recombinant SENP1 or an antigenic fragment thereof, is isolated and purified, *e.g.,* following recombinant expression in eukaryotic or prokaryotic cells. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

Monoclonal antibodies and polyclonal sera can be collected and titered against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Typically, polyclonal antisera with a titer of  $10^4$  or greater are selected and tested for their cross reactivity against non-SENP1 or telomerase proteins, using a competitive binding immunoassay. Specific polyclonal antisera and monoclonal antibodies will usually bind with a  $K_d$  of at least about 0.1 mM, more usually at least about 1  $\mu$ M, optionally at least about 0.1  $\mu$ M or better, and optionally 0.01  $\mu$ M or better.

- 44 -

Once SENP1 and/or telomerase-specific antibodies are available, SENP1 or telomerase polypeptides can be detected by a variety of immunoassay methods. For a review of immunological and immunoassay procedures, see *Basic and Clinical Immunology* (Stites & Terr eds., 7th ed. 1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay* (Maggio, ed., 1980); and Harlow & Lane, *supra*.

SENP1 and/or telomerase polypeptides can be detected and/or quantified using any of a number of well recognized immunological binding assays (*see, e.g.*, U.S. Pat. Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed. 1991). Immunological binding assays (or immunoassays) typically use an antibody that specifically binds to a protein or antigen of choice (in this case the SENP1 or telomerase polypeptides or antigenic subsequence thereof). The antibody (e.g., anti-SENP1 or anti-telomerase) may be produced by any of a number of means well known to those of skill in the art and as described above.

Immunoassays also often use a labeling agent to specifically bind to and label the complex formed by the antibody and antigen. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent may be a labeled SENP1 or telomerase polypeptide or a labeled anti-SENP1 or anti-telomerase antibody. Alternatively, the labeling agent may be a third moiety, such a secondary antibody, that specifically binds to the antibody/SENP1 or antibody/telomerase complex (a secondary antibody is typically specific to antibodies of the species from which the first antibody is derived). Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (*see, e.g.*, Kronval *et al.*, *J. Immunol.* 111 (1973) 1401-1406; Akerstrom *et al.*, *J. Immunol.* 135 (1985) 2589-2542). The labeling agent can be modified with a detectable moiety, such as biotin, to which another molecule can specifically

- 45 -

bind, such as streptavidin. A variety of detectable moieties are well known to those skilled in the art.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several  
5 hours, optionally from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10° C to 40° C.

10 Immunoassays for detecting SENP1 or telomerase polypeptides in samples may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of antigen is directly measured. In "sandwich" assays, for example, the anti-SENP1 or anti-telomerase antibodies can be bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then  
15 capture SENP1 or telomerase polypeptides present in the test sample. The SENP1 or telomerase polypeptide thus immobilized is then bound by a labeling agent, such as a second anti-SENP1 or anti-telomerase antibody bearing a label. Alternatively, the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody  
20 is derived. The second or third antibody is typically modified with a detectable moiety, such as biotin, to which another molecule specifically binds, e.g., streptavidin, to provide a detectable moiety.

In competitive assays, the amount of SENP1 or telomerase polypeptide present in the sample is measured indirectly by measuring the amount of a known, added  
25 (exogenous) SENP1 or telomerase polypeptide displaced (competed away) from an anti-SENP1 or anti-telomerase antibody by the unknown SENP1 or telomerase polypeptide present in a sample. In one competitive assay, a known amount of SENP1 or telomerase polypeptide is added to a sample and the sample is then contacted with an antibody that specifically binds to the SENP1 or telomerase  
30 polypeptide. The amount of exogenous SENP1 or telomerase polypeptide bound to the antibody is inversely proportional to the concentration of SENP1 or telomerase polypeptide present in the sample. In some embodiments, the antibody is

- 46 -

immobilized on a solid substrate. The amount of SENP1 or telomerase polypeptide bound to the antibody may be determined either by measuring the amount of SENP1 or telomerase polypeptide present in a SENP1/antibody or telomerase/antibody complex, or alternatively by measuring the amount of remaining uncomplexed protein.

5 Western blot (immunoblot) analysis can also be used to detect and quantify the presence of SENP1 or telomerase polypeptides in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind SENP1 or telomerase. The anti-SENP1 or anti-telomerase antibodies specifically bind to the SENP1 or telomerase on the solid support. These antibodies may be directly labeled or, alternatively, may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-SENP1 or anti-telomerase antibodies.

10 One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used.

25 The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the

30

present invention include magnetic beads, fluorescent dyes, radiolabels, enzymes, and colorimetric labels such as colloidal gold or colored glass or plastic beads.

**D. Detection and quantification of SENP1 or telomerase activity**

5 The quantity of SENP1 or telomerase can also be determined by detecting the activity of the proteins.

SENP1 is a protease that removes sentrins from proteins. *See, e.g.*, U.S. Patent No. 6,596,527; Gong *et al.*, *J Biol Chem.* 275 (2000) 3355-3359; and Bailey *et al.*, *J Biol Chem.* 279 (2004) 692-703. For instance, SENP1 activity can be detected by  
10 detecting removal of sentrins from a known amount of sentrinized protein in the sample.

Telomerase activity can be measured by any number of assays known in the art. *See, e.g.*, Hiyama *et al.*, *Cancer Lett.* 194 (2003) 221-233. For example, TRAP (telomeric repeat amplification protocol) can be used for detecting telomerase  
15 activity with a high sensitivity by using PCR. *See*, Kim N. W. *et al.*, *Science* 206 (1994) 2011-2015; Piatyszek M. A. *et al.*, *Meth. Cell Sci.* 17 (1995) 1-15; Woodring *et al.*, *Nuc. Acids Res.* 23 (1995) 3794-3795; U.S. Patent Nos. 6,551,774; 6,391,554; and 5,837,453. This method involves the detection of telomerase by a single primer extension assay system and is roughly divided in three steps. First,  
20 telomerase is extracted from cells. Then, an extension reaction of a TTAGGG chain by the telomerase is carried out and the reaction products are amplified by PCR using two primers. Finally, the amplified products are electrophoresed to detect the telomerase activity by confirming ladders in autoradiography.

A variation of TRAP involves SYBR Green in real-time to quantify telomerase  
25 activity. *See, e.g.*, Wege *et al.*, *Nuc. Acids Res.* 31 (2003) e3.

Another variation of TRAP is called telomeric extension-PCR (PTEP). *See, e.g.*, Chen *et al.*, *Biotechniques* 35 (2003) 158-162. Similar to TRAP, this method is based on PCR amplification following the in vitro telomerase reaction, while the in vitro telomerase reaction here is prematurely, rather than randomly, terminated.

30 Apart from this, the telomeric extension products are used as initial primers, instead of as templates, to trigger the amplification with a specially constructed plasmid

DNA as the template that cannot be directly amplified with the telomerase primer. The end product is a specific DNA fragment that reflects telomerase activity. Those of skill in the art will recognize that other methods can also be used to detect telomerase activity. *See, e.g.*, U.S. Patent Publication No. 2002/0025518.

5

### ***III. Quantification Standards For Assays Of The Inventions***

In many embodiments of the invention, the quantity of SENP1 or telomerase in a biological sample is compared to one or more standard values. In general, the standard value will represent the quantity of SENP1 or telomerase found in biological samples from a healthy individual (e.g., not diagnosed with cancer and/or not containing a significant number of cancer cells). Different standard values will be appropriate depending on a number of factors. For example, the quantity of SENP1 or telomerase in a sample from a healthy individual can vary depending on the method used for quantifying SENP1 or telomerase. Moreover, the standard value can vary depending on the proportion of false positives and false negatives that will be provided in a diagnostic assay. For example, if the standard value is set at a low value, the number of false negatives will decrease but the proportion of false positives (those without cancer that are scored as having cancer cells) will increase. Thus, a user can compare SENP1 or telomerase quantity in a sample to different standard values depending on the tolerance for false negative or false positive results.

In some cases, the standard value will be determined based on the average, median, or other statistical calculation based on a plurality of samples either known to lack cancer cells or known to contain cancer cells. The standard value need not be recalculated for each assay, but can be a pre-determined single value or range. The standard value can be stored in a computer memory and accessed as necessary.

In other embodiments, the standard value is determined for each biological sample each time a set of biological samples are processed. In these cases, the standard value is the quantity of SENP1 or telomerase in a sample known, or at least suspected, to not contain cancer cells. In some embodiments, these standard samples will be collected from the same individual as is tested for cancer. For example, a solid tumor and a non-cancer-containing sample can be obtained from

30

- 49 -

the same individual and the quantity of SENP1 and/or telomerase in the non-cancer-containing sample can form the basis of the standard value. In other embodiments, the standard samples will be obtained from another individual or individuals.

5 In some cases, the quantities of SENP1 or telomerase (both from the biological sample of interest and the non-cancer standard) are normalized to a second value. Normalization is useful, for example, to remove or minimize error introduced by a user or assays into the amounts detected or to minimize error caused by varying numbers of cells in a sample. Normalization is typically based on a value that  
10 incorporates some of the same errors. For example, the quantity of a second transcript in the same biological sample can be used to normalize SENP1 or telomerase values. Typically, the second transcript is known or suspected not to be effected by the presence or absence of cancer cells in the sample. Exemplary "normalizing transcripts" (also known as transcripts of "housekeeping genes")  
15 include, but are not limited to, the following human proteins: protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA), TATA box binding protein (e.g., M55654), HPRT1 (e.g., M26434),  $\beta$ -glucuronidase,  $\beta$ 2-microglobulin, phosphoglycerol kinase 1 (e.g., NM\_000291),  $\beta$ -actin (e.g., NM\_001101), transferrin receptor (e.g., NM\_003234), glyceraldehyde-3-phosphate  
20 dehydrogenase (e.g., NM\_002046), human serum albumin (e.g., NM\_000477), tubulin, hypoxanthine phosphoribosyltransferase (e.g., NM\_000194), mitochondrial ribosomal protein L32 (e.g., NM\_031903), 28S RNA, 18S RNA, 5-aminolevulinate synthase, and porphobilinogen deaminase. *See also*, LightCycler h-Housekeeping Gene Selection Set (Roche Applied Sciences, catalog no. 3310159); Thellin, O. *et al.*, *J. Biotechnol.* 75 (1999) 291; Warrington, J.A. *et al.*, *Physiol. Genomics* 2  
25 (2000) 143. Those of skill in the art will recognize that many house keeping genes, among others, will provide equivalent normalizing values. Values can be normalized according to any generally known statistical methods, including by simply dividing values by the quantity of the normalizing transcript or protein.

30

- 50 -

#### ***IV. Recording A Diagnosis, Prognosis Or Stage Of Cancer***

The methods of the invention may involve recording the quantity of SENP1 and/or telomerase in a sample and/or a diagnosis, prognosis, or stage of cancer, including, e.g., bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer,  
5 ovarian cancer, pancreatic cancer, and small intestine cancer.

This information may be recorded as text or data and may be stored in a computer readable form. Such a computer system typically comprises major subsystems such as a central processor, a system memory (typically RAM), an input/output (I/O) controller, an external device such as a display screen via a display adapter,  
10 serial ports, a keyboard, a fixed disk drive via a storage interface and a floppy disk drive operative to receive a floppy disc, and a CD-ROM (or DVD-ROM) device operative to receive a CD-ROM. Many other devices can be connected, such as a network interface connected via a serial port.

The computer system also be linked to a network, comprising a plurality of  
15 computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern  
20 encoding data acquired from an assay of the invention.

The computer system can comprise code for interpreting the results of quantification of SENP1 or telomerase in a biological sample. Thus in an exemplary embodiment, the genotype results are provided to a computer where a central processor is executes a computer program for determining a diagnosis,  
25 prognosis or determination of the stage of a particular cancer, e.g., selected from bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

#### ***V. Diagnosing Cancer***

30 The present methods can be used in the diagnosis, prognosis, classification, and treatment of a number of types of cancers. A cancer at any stage of progression can be detected, such as primary, metastatic, and recurrent cancers. Information

regarding numerous types of cancer can be found, e.g., from the American Cancer Society ([www.cancer.org](http://www.cancer.org)), or from, e.g., Wilson *et al.* (1991) *Harrison's Principles of Internal Medicine*, 12th Edition, McGraw-Hill, Inc. Exemplary cancers that can be detected include, e.g., carcinomas, gliomas, mesotheliomas, melanomas, lymphomas, leukemias, adenocarcinomas, breast cancer, ovarian cancer, cervical cancer, glioblastoma, leukemia, lymphoma, prostate cancer, and Burkitt's lymphoma, head and neck cancer, colon cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, cancer of the esophagus, stomach cancer, pancreatic cancer, hepatobiliary cancer, cancer of the gallbladder, cancer of the small intestine, rectal cancer, kidney cancer, bladder cancer, prostate cancer, penile cancer, urethral cancer, testicular cancer, cervical cancer, vaginal cancer, uterine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, pancreatic endocrine cancer, carcinoid cancer, bone cancer, skin cancer, retinoblastomas, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. See *Cancer: Principles and Practice* (DeVita, V.T. *et al.* eds 1997) for additional cancers.

The present invention provides methods for determining whether or not a mammal (e.g., a human) has cancer, whether or not a biological sample contains cancerous cells, estimating the likelihood of a mammal developing cancer, and monitoring the efficacy of anti-cancer treatment in a mammal with cancer. Such methods are based on the discovery that cancer cells have an elevated level of SENP1 polynucleotide and/or polypeptide. Accordingly, by determining whether or not a cell contains elevated levels of SENP1 or telomerase, it is possible to determine whether or not the cell is cancerous. Further, the presence of cancerous cells can be determined indirectly, e.g., in certain embodiments a biological sample that does not itself contain cancerous cells, but which has been taken from an animal with cancerous cells elsewhere in its body, may contain elevated levels of SENP1 or telomerase reflecting the presence of the cancerous cells.

In numerous embodiments of the present invention, the level and/or presence of SENP1 or telomerase will be detected in a biological sample, thereby detecting the presence or absence of cancerous cells in the biological sample, or, in certain embodiments, in the mammal from which the biological sample was removed. In some embodiments, the biological sample will comprise a tissue sample from a

- 52 -

tissue suspected of containing cancerous cells. For example, in an individual suspected of having bladder cancer, bladder tissue is biopsied, or urine is obtained. In other embodiments, the quantity of SENP1 or telomerase is determined in a bodily fluid (e.g., urine sediment (*see, e.g., Melissourgos et al., Urology 62 (2003) 362-367*), saliva, blood, semen, etc.). In some embodiments, the quantity of SENP1 in a biopsy from a tissue selected from breast, colon, kidney, lung, ovarian, pancreatic, and small intestine is used to detect cancer in that tissue. In some embodiments, the quantity of SENP1 in a bronchial lavage is determined, e.g., to diagnose lung cancer. In some embodiments, the quantity of SENP1 is determined from a stool sample, e.g., to diagnose colon or small intestine cancer. In other embodiments, a tissue sample known to contain cancerous cells, e.g., from a tumor, will be analyzed for SENP1 or telomerase levels to determine information about the cancer, e.g., the efficacy of certain treatments, the survival expectancy of the animal, etc. Often, the methods will be used in conjunction with additional diagnostic methods, e.g., detection of other cancer markers, etc.

Further, the present methods may be used to assess the efficacy of a course of treatment. For example, in a mammal with cancer from which a biological sample has been found to contain an elevated amount of a SENP1 or telomerase, the efficacy of an anti-cancer treatment can be assessed by monitoring SENP1 or telomerase levels over time. For example, a reduction in SENP1 or telomerase levels in a biological sample taken from a mammal following a treatment, compared to a level in a sample taken from the mammal before, or earlier in, the treatment, indicates efficacious treatment.

The methods detecting cancer can comprise the detection of one or more other cancer-associated polynucleotide or polypeptides sequences. Accordingly, SENP1 or telomerase can be used either alone, together or in combination with other markers for the diagnosis or prognosis of cancer.

The methods of the present invention can be used to determine the optimal course of treatment in a mammal with cancer. For example, the presence of an elevated level of SENP1 or telomerase can indicate a reduced survival expectancy of a mammal with cancer, thereby indicating a more aggressive treatment for the mammal. In addition, a correlation can be readily established between levels of

- 53 -

SENP1 or telomerase, or the presence or absence of a diagnostic presence of  
SENP1 or telomerase (i.e., a quantity of SENP1 or telomerase over the standard  
value), and the relative efficacy of one or another anti-cancer agent. Such analyses  
can be performed, e.g., retrospectively, i.e., by detecting SENP1 or telomerase  
5 levels in samples taken previously from mammals that have subsequently  
undergone one or more types of anti-cancer therapy, and correlating the SENP1 or  
telomerase levels with the known efficacy of the treatment.

In making a diagnosis, prognosis, risk assessment or classification, based on  
expression of SENP1 and/or telomerase, the quantity of SENP1 and/or telomerase  
10 expression may be compared to a standard value, as discussed above. In some  
cases, a diagnosis or prognosis of cancer can be made if SENP1 and/or telomerase  
expression in the biological sample is higher than the standard value. In some  
cases, the quantity of SENP1 and/or telomerase expression in the biological sample  
is at least 10% more, 25% more, 50% more, 75% more, 90% more, 2-fold, 3-fold,  
15 5-fold, 10-fold, 50-fold, or more than 100-fold compared to the standard value (or a  
value representing SENP1 and/or telomerase expression in a non-cancer containing  
sample).

#### ***VI. Sample Preparation and Nucleic Acid Amplification***

20 Samples are generally derived or isolated from subjects, typically mammalian  
subjects, more typically human subjects. Essentially any technique for acquiring  
these samples is optionally utilized including, e.g., biopsy, scraping, venipuncture,  
swabbing, or other techniques known in the art.

Methods of storing specimens, culturing cells, isolating and preparing nucleic acids  
25 from these sources are generally known in the art and many of these are described  
further in the references and/or examples provided herein.

To further illustrate, prior to analyzing the target nucleic acids described herein,  
those nucleic acids may be purified or isolated from samples that typically include  
complex mixtures of different components. Cells in collected samples are typically  
30 lysed to release the cell contents. For example, cells in urine sediment can be lysed  
by contacting them with various enzymes, chemicals, and/or lysed by other  
approaches known in the art. In some embodiments, nucleic acids are analyzed

- 54 -

directly in the cell lysate. In other embodiments, nucleic acids are further purified or extracted from cell lysates prior to detection. Essentially any nucleic acid extraction methods can be used to purify nucleic acids in the samples utilized in the methods of the present invention. Exemplary techniques that can be used to purifying nucleic acids include, e.g., affinity chromatography, hybridization to probes immobilized on solid supports, liquid-liquid extraction (e.g., phenol-chloroform extraction, etc.), precipitation (e.g., using ethanol, etc.), extraction with filter paper, extraction with micelle-forming reagents (e.g., cetyl-trimethyl-ammonium-bromide, etc.), binding to immobilized intercalating dyes (e.g., ethidium bromide, acridine, etc.), adsorption to silica gel or diatomic earths, adsorption to magnetic glass particles or organo silane particles under chaotropic conditions, and/or the like. Sample processing is also described in, e.g., US Pat. Nos. 5,155,018, 6,383,393, and 5,234,809.

To further exemplify, unmodified nucleic acids can bind to a material with a silica surface. Many of the processes that are optionally adapted for use in performing the methods of the present invention are described in the art. To illustrate, Vogelstein *et al.*, *Proc. Natl. Acad. Sci. USA* 76 (1979) 615-619 describes the purification of nucleic acids from agarose gels in the presence of sodium iodide using ground flint glass. Marko *et al.*, *Anal. Biochem.* 121 (1982) 382-387 describes the purification of nucleic acids from bacteria on glass dust in the presence of sodium perchlorate. In DE-A 3734442 nucleic acids are isolated on glass fiber filters. The nucleic acids bound to these glass fiber filters are washed and then eluted with a methanol-containing Tris/EDTA buffer. A similar procedure is described in Jakobi *et al.*, *Anal. Biochem.* 175 (1988) 196-201. In particular, Jakobi *et al.* describes the selective binding of nucleic acids to glass surfaces in chaotropic salt solutions and separating the nucleic acids from contaminants, such as agarose, proteins, and cell residue. To separate the glass particles from the contaminants, the particles can be centrifuged or fluids can be drawn through the glass fiber filters. In addition, the use of magnetic particles to immobilize nucleic acids after precipitation by adding salt and ethanol is described in, e.g., Alderton *et al.*, *Anal. Biochem.* 201 (1992) 166-169 and PCT/GB91/00212. In this procedure, the nucleic acids are agglutinated along with the magnetic

- 55 -

particles. The agglutinate is separated from the original solvent by applying a magnetic field and performing one or more washing steps. After at least one wash step, the nucleic acids are typically dissolved in a Tris buffer.

5 Magnetic particles in a porous glass matrix that is covered with a layer that includes, e.g., streptavidin can also be utilized in certain embodiments of the invention. These particles can be used, e.g., to isolate biotin-conjugated nucleic acids and proteins. Ferrimagnetic, ferromagnetic, and superparamagnetic particles are also optionally utilized. Magnetic glass particles and related methods that can be adapted for using in performing the methods described herein are also described  
10 in, e.g., WO 01/37291.

#### Via. Preferred embodiments of the invention

Particularly preferred embodiments of the invention are described in the following. A preferred embodiment of the invention is a method of detecting SENP1  
15 expression in a biological sample, the method comprising the steps of determining the quantity of SENP1 in a biological sample from an individual having or suspected of having a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

20 The method may optionally comprise the step of obtaining the biological sample from the individual before determining the quantity of SENP1 in the biological sample. Preferably, the method further comprises the step of recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer,  
25 kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

In a preferred embodiment, the quantity of SENP1 is determined by detecting a polynucleotide encoding SENP1 in the sample. Therefore, preferably the step of  
30 determining the quantity of SENP1 comprises the step of detecting a polynucleotide encoding SENP1 in the sample. This detection step may comprise amplifying the polynucleotide in an amplification reaction. Preferably, the

- 56 -

amplification reaction comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1.

5 Preferably, the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. Preferably, the amplification reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide.

10 In a preferred embodiment, the method may further comprise the step of determining the quantity of telomerase in the biological sample. Preferably, the method further comprises the step of comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells  
15 and the telomerase standard represents telomerase quantities in non-cancer cells.

In summary, in a preferred embodiment of the invention, a method of detecting SENP1 expression is provided in a biological sample from an individual having or suspected of having a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and  
20 small intestine cancer, the method comprising determining the quantity of SENP1 in the biological sample by

a) amplifying a polynucleotide encoding SENP1 in the biological sample in an amplification reaction, and  
b) detecting the amount of the amplification product of step a) to detect SENP1  
25 expression in the biological sample.

Preferably, the amplification reaction comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during  
30 the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1.

- 57 -

Preferably, the (amount of the) amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. Preferably, the amplification reaction further comprises a template-  
5 dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide. In a preferred embodiment, the method may further comprise the step of determining the quantity of telomerase in the biological sample. Preferably, the method further comprises the step of comparing the quantity of SENP1 and  
10 telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells. The standard is preferably a biological sample (comprising cells) from a control individual not suffering from bladder cancer, breast cancer, colon cancer, kidney  
15 cancer, lung cancer, ovarian cancer, or pancreatic cancer. The method may optionally comprise the step of obtaining the biological sample from the individual before the determining the quantity of SENP1 in the biological sample. Preferably, the method further comprises the step of recording a diagnosis of a cancer selected from the group consisting of bladder cancer, breast cancer,  
20 colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

In another preferred embodiment of the invention, a method is provided to determine whether a biological sample from a patient comprises cancerous cells  
25 selected from the group consisting of bladder cancer cells, breast cancer cells, colon cancer cells, kidney cancer cells, lung cancer cells, ovarian cancer cells, pancreatic cancer cells, and small intestine cancer cells comprising the steps of

- a) determining the quantity of SENP1 in the biological sample,
- b) determining the quantity of SENP1 in a biological sample from a control  
30 individual not suffering from bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, or pancreatic cancer,

- 58 -

a significant difference between the quantity of SENP1 in the biological sample from the patient and the quantity of SENP1 in the biological sample from the control individual is an indication that the biological sample comprises cancer cells.

5

A significant difference is preferably a 1.5 fold or greater difference, more preferably a two fold or greater difference.

The step of determining the quantity of SENP1 in the biological sample preferably comprises the steps of

10

- a) amplifying a polynucleotide encoding SENP1 in the biological sample in an amplification reaction, and
- b) detecting the amount of the amplification product of step a) to determine the quantity of SENP1 in the biological sample.

15

Preferably, the amplification reaction comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1.

20

Preferably, the (amount of the) amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. Preferably, the amplification reaction further comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide.

25

In a preferred embodiment, the method may further comprise the step of determining the quantity of telomerase in the biological sample. Preferably, the method further comprises the step of comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard,

30

respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells.

- 59 -

The standard is preferably a biological sample (comprising cells) from a control individual not suffering from bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, or pancreatic cancer.

5 The method may optionally comprise the step of obtaining the biological sample from the individual before the determining the quantity of SENP1 in the biological sample. Preferably, the method further comprises the step of recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

10

### *VII. Kits*

The present invention also provides for kits for diagnosing cancer by detecting SENP1 and telomerase (e.g., polynucleotides, polypeptides, or activity). The kits of the invention will generally comprise reagents for detecting SENP1 and/or telomerase polypeptides and/or SENP1 and/or telomerase polynucleotides, and will optionally contain written instructions for their use.

15 In some embodiments, the kits of the invention will comprise reagents to amplify SENP1 and/or telomerase polynucleotides. Such reagents can include, e.g., SENP1 and/or telomerase-specific primers and/or detectably labeled probes (e.g., 5' exonuclease, molecular beacon or Scorpion probes). The kits can optionally include amplification reagents such as thermostable polymerases, reverse transcriptase, nucleotides, buffers and salts or other components as described herein or known in the art.

25 In some cases, the kits will comprise at least one oligonucleotide comprising a sequence at least 70%, 75%, 80%, 85%, 90% or 95% identical to at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 35, 50 or more contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that when the oligonucleotide and a polynucleotide comprising SEQ ID NO:1 are submitted to an amplification reaction, the oligonucleotide primes amplification of at least a fragment of SEQ ID NO:1.

30

In some cases, the kits will also comprise the detectably-labeled oligonucleotide comprising a sequence at least 70%, 75%, 80%, 85%, 90% or 95% identical to at

- 60 -

least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 35, 50 or more contiguous nucleotides of SEQ ID NO:1, or a complement thereof.

In some cases, the kits will comprise at least one oligonucleotide comprising a sequence at least 70%, 75%, 80%, 85%, 90% or 95% identical to at least 5, 6, 7, 8,  
5 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 35, 50 or more contiguous nucleotides of:

- i) human telomerase RNA (TERC);
- ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- 10 iii) a complement of TERC; or
- iv) a complement of TERT

such that when the oligonucleotide and TERC or TERT mRNA are submitted to an amplification reaction, the oligonucleotide primes amplification of at least a fragment of TERC or TERT mRNA.

15 In some cases, the kits will comprise the detectably-labeled oligonucleotide comprising a sequence at least 70%, 75%, 80%, 85%, 90% or 95% identical to at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 35, 50 or more contiguous nucleotides of:

- i) human telomerase RNA (TERC);
- 20 ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- iii) a complement of TERC; or
- iv) a complement of TERT.

In other embodiments, the kits of the invention comprise reagents that specifically  
25 bind to SENP1 or telomerase polypeptides. For example, in some embodiments, the kits of the invention comprise a first antibody that specifically binds to SENP1 or telomerase. The kits can also comprise a second antibody that binds to the first antibody (i.e., from a different species) and a detectable label.

### 30 **VIII. Screening for Antagonists of SENP1**

A number of different screening protocols can be utilized to identify agents that modulate the level of activity of SENP1 in cells, e.g., in mammalian cells, e.g., in

- 61 -

human cells. In general terms, the screening methods may involve screening a plurality of agents to identify an agent that interacts with SENP1, for example, by binding to SENP1 and preventing activity of SENP1 or by preventing an activator of SENP1 from activating SENP1.

5

#### 1. SENP1 Binding Assays

Preliminary screens can be conducted by screening for agents capable of binding to SENP1, as at least some of the agents so identified may be SENP1 antagonists. The binding assays usually involve contacting a SENP1 protein with one or more test agents and allowing sufficient time for the protein and test agents to form a binding complex. Any binding complexes formed can be detected using any of a number of established analytical techniques. Protein binding assays include, but are not limited to, immunohistochemical binding assays, flow cytometry or other assays which maintain conformation of SENP1. SENP1 utilized in such assays can be naturally expressed, cloned or synthesized.

10

15

Binding assays are also useful, e.g., for identifying endogenous proteins that interact with SENP1.

#### 2. Cells and Reagents

The screening methods of the invention can be performed as *in vitro* or cell-based assays. Cell-based assays can be performed in any cells in which a SENP1 polypeptide is endogenously or exogenously expressed. In some embodiments, the cell-based assays may be performed using cells that have reduced or no detectable telomerase activity or expression and/or that have a neoplastic phenotype. In some

20

25

30

embodiments, TERT expression-negative immortal cell lines are tested for susceptibility to potential SENP1 inhibitors. These telomerase-negative cell lines are proposed to be useful in such a screen since they likely replicate their telomeres by a telomerase-independent mechanism (Alternative Lengthening of Telomeres or "ALT"). Without intending to limit the scope of the invention to a particular mechanism of action, we propose that SENP1 is involved in the maintenance of ALT. Inhibition of ALT by a SENP1 inhibitor would then be predicted to result in an alteration of the telomere structure with an eventual inhibition of division of

- 62 -

these cells. In contrast, in cases where telomerase is active in cell-lines, the telomerase would continue to allow for cell division even in the presence of a SENP1 inhibitor.

5 Examples of cells that do not express telomerase ("ALT" cells) are known in the literature. *See, e.g.*, Tsutsui, T *et al.* *Carcinogenesis* 24 (2003) 953-965; Bryan, T.M., *Hum Mol Genet* 6 (1997) 921-926; Guilleret, I. *et al.*, *Carcinogenesis* 23 (2002) 2025-2030. Examples of ALT cell lines include, but are not limited to, SUSM-1, WI38 VA13/2RA, BET-3M, GM847, MeT-4A, IICF/c, IICF-T/A6, MDAH 087, Saos-2 and U-2 cells.

10 Inhibition of ALT can be detected by assaying for a change in telomere length (*see, e.g.*, the TeloTAGGG Telomere Length Assay from Roche Applied Biosystems or Tsutsui, T. *et al.*, *Carcinogenesis* 24 (2003) 953-965), or a change in morphological markers such as the presence of PML bodies that are "donut-shaped" in ALT cells instead of the normally punctate appearance of PML-NB in

15 cells not undergoing ALT (*see, e.g.*, Yeager, T.R., et al., *Cancer Res.* 59 (1999) 4175-4179, inhibition of cell division (determined by, e.g., counting the number of cells at different time points (e.g., using Guava Technology™ products), using soft agar based assays to count the number of colonies at different time points, using cell staging technology to determine the stage of the cell cycle the cells are in,

20 visually analyzing cell using microscopy, chromosomal analyses or Cellomics™ technology, or analyzing protein expression, e.g., via western blotting or immunohistochemical analyses).

Cell-based assays may involve whole cells or cell fractions containing SENP1 to screen for agent binding or modulation of SENP1 activity by the agent. Cells used

25 in the cell-based assays may be primary cells or tumor cells or other types of immortal cell lines. Of course, SENP1 can be expressed in cells that do not endogenously express SENP1.

### 3. Signaling activity or downstream events

30 Signaling activity or other downstream events regulated by SENP1 can also be monitored to identify SENP1 antagonists. Thus, in some embodiments, a plurality of agents are contacted to a cell expressing SENP1 and the cells are subsequently

- 63 -

5 screened for a change in signaling or a downstream event. The pool of agents that modulate a downstream event regulated by SENP1 are typically enriched for SENP1 antagonists because at least some of the identified agents are likely to directly antagonize SENP1. Downstream events include those activities or  
10 manifestations that occur as a result of inhibition of SENP1, and may include, e.g.: reduced cell growth (measured, e.g., as colony counts in soft agar or using cell analysis systems such as those from Guava Technologies, Hayward, CA), changes in cell cycle stage (measured, e.g., using HT antibody staining image analysis, e.g., from Cellomics, Pittsburgh, PA, or by standard cytological methods);  
15 or changes in protein expression, including, e.g., by western blotting or microscopy.

*Soft agar growth or colony formation in suspension*

15 Normal cells require a solid substrate to attach and grow. Neoplastic cells have lost this phenotype and grow detached from the substrate. For example, neoplastic cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The neoplastic cells, when transfected with tumor suppressor genes or when contacted with a SENP1 antagonist, may regenerate normal phenotype and may require a solid substrate to attach and grow. Thus, soft  
20 agar growth or colony formation in suspension assays can be used to identify agents that reduce or eliminate abnormal cellular proliferation and transformation, including soft agar growth.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, *Culture of Animal Cells a Manual of Basic Technique* (3<sup>rd</sup>  
25 ed., 1994), herein incorporated by reference.

*Contact inhibition and density limitation of growth*

30 Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can



- 65 -

Various techniques which measure the release of these factors are described in Freshney (1994), *supra*. Also, see, Unkless *et al.*, *J. Biol. Chem.* 249 (1974) 4295-4305; Strickland & Beers, *J. Biol. Chem.* 251 (1976) 5694-5702; Whur *et al.*, *Br. J. Cancer* 42 (1980) 305-312; Gullino, *Angiogenesis, tumor vascularization, and potential interference with tumor growth*, in *Biological Responses in Cancer*, pp. 178-184 (Mihich (ed.) 1985); Freshney *Anticancer Res.* 5 (1985) 111-130.

#### *Invasiveness into Matrigel*

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used in an assay to identify SENP1 antagonists. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, neoplastic cells may be used, wherein a decrease invasiveness of the cells following contacted with an agent may indicate that the agent is a SENP1 antagonist.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with  $^{125}\text{I}$  and counting the radioactivity on the distal side of the filter or bottom of the dish. See, *e.g.*, Freshney (1984), *supra*.

#### 4. Validation

Agents that are initially identified by any of the foregoing screening methods can be further tested to validate the apparent activity. In some embodiments, such studies are conducted with suitable animal models. The basic format of such methods involves administering a lead compound identified during an initial screen to an animal that serves as a model for human disease to be treated and then determining if SENP1 is in fact modulated and/or the disease or condition is ameliorated. The animal models utilized in validation studies generally are mammals of any kind. Specific examples of suitable animals include, but are not limited to, primates, mice and rats.

### 5. Agents that interact with SENP1

The agents tested as modulators of SENP1 can be any small chemical compound, or a biological entity, such as a polypeptide (e.g., a peptide), sugar, nucleic acid (including, e.g., siRNAs or antisense polynucleotides) or lipid. Essentially any chemical compound can be used as a potential modulator (e.g., antagonist) or ligand in the assays of the invention, although most often compounds that can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs, Switzerland) and the like.

In some embodiments, the agents have a molecular weight of less than 1,500 daltons, and in some cases less than 1,000, 800, 600, 500, or 400 daltons. The relatively small size of the agents can be desirable because smaller molecules have a higher likelihood of having physiochemical properties compatible with good pharmacokinetic characteristics, including oral absorption than agents with higher molecular weight. For example, agents less likely to be successful as drugs based on permeability and solubility were described by Lipinski *et al.* as follows: having more than 5 H-bond donors (expressed as the sum of OHs and NHs); having a molecular weight over 500; having a LogP over 5 (or MLogP over 4.15); and/or having more than 10 H-bond acceptors (expressed as the sum of Ns and Os). See, e.g., Lipinski *et al. Adv Drug Delivery Res* 23 (1997) 3-25.

In some embodiments, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The

compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (*i.e.*, the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent 5,010,175, Furka, *Int. J. Pept. Prot. Res.* 37 (1991) 487-493; and Houghton *et al.*, *Nature* 354 (1991) 84-88). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (*e.g.*, PCT Publication No. WO 91/19735), encoded peptides (*e.g.*, PCT Publication WO 93/20242), random bio-oligomers (*e.g.*, PCT Publication No. WO 92/00091), benzodiazepines (*e.g.*, U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci. USA* 90 (1993) 6909-6913), vinylogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114 (1992) 6568), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer. Chem. Soc.* 114 (1992) 9217-9218), analogous organic syntheses of small compound libraries (Chen *et al.*, *J. Amer. Chem. Soc.* 116 (1994) 2661), oligocarbamates (Cho *et al.*, *Science* 261 (1993) 1303), and/or peptidyl phosphonates (Campbell *et al.*, *J. Org. Chem.* 59 (1994) 658), nucleic acid libraries (*see* Ausubel, Berger and Sambrook, all *supra*), peptide nucleic acid libraries (*see, e.g.*, U.S. Patent 5,539,083), antibody libraries (*see, e.g.*, Vaughn *et al.*, *Nature Biotechnology*, 14 (1996) 309-314 and PCT/US96/10287), carbohydrate libraries (*see, e.g.*, Liang *et al.*, *Science*, 274 (1996) 1520-1522) and U.S. Patent 5,593,853), small organic molecule libraries (*see, e.g.*, benzodiazepines, Baum C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent 5,569,588; thiazolidinones and

- 68 -

metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent 5,506,337; benzodiazepines, 5,288,514, and the like).

5 Devices for the preparation of combinatorial libraries are commercially available (*see, e.g.*, 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). In addition, numerous combinatorial libraries are themselves commercially available (*see, e.g.*, ComGenex, Princeton, N.J., Tripos, Inc., St. Louis, MO, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, 10 Columbia, MD, etc.).

SENP1 is structurally related to the ubiquitin family of proteins and this similarity can be used to assist in designing SENP1 antagonists. The family of Small Ubiquitin-Like (Ubl) Modifiers (SUMO; reviewed in Muller, S., *et al.*, *Nat Rev Mol Cell Biol* 2 (2001) 202-210) and Yeh, E.T., *et al.*, *Gene* 248 (2000) 1-14), of 15 which SENP1 is a member, is related to the Ubiquitin family. Although sequence identity between the two families is <20%, the overall structures are very similar (2.1 Å rmsd for core residues [21-93 and 1-72 of SUMO-1 and ubiquitin, respectively] (Bayer, P., *et al.*, *J Mol Biol.* 280 (1998) 275-286). Both proteins become covalently attached via their C-terminal -COOH group to the ε-NH<sub>2</sub> group 20 of a Lysine side chain (isopeptide bond) of the target protein. Ubiquitin and SUMO possess conserved di-Glycine motifs near the C-terminus. The conjugation of Ubiquitin and SUMO is a complex process that involves several steps: C-tail cleavage, activation and final transfer (Johnson, E.S., *et al.*, *Embo J* 16 (1997) 5509-5519; Gong, L., *et al.*, *FEBS Lett* 448 (1999) 185-189).

25 Unlike ubiquitin, SUMOs do not form polymeric attachments due to substitution of the equivalent to Ubiquitin Lys-48 with Gln. The SUMO and ubiquitin pathways differ primarily in the consequence of the modification: the most well characterized result of ubiquitination is the targeting of the tagged protein to the 26 S proteasome for degradation. SUMOylated proteins are not destined for degradation.

30 Three SUMO genes have been identified in humans (see Table 1 for accession numbers). There is 62.0/49.0% sequence similarity/identity between Smt3 and

human SUMO-1 (see Table 2). The solution structure for human SUMO-1 has been solved (Bayer, P., *et al.*, *J Mol Biol.* 280 (1998) 275-286).

5

**Table 1:** Sequences (SWISSPROT accession numbers), Pfam motifs and Structures (PDB files).

<u>Sequence/Motif/Structure</u>	<u>Description</u>
YEASTGP:ULP1	<i>S. cerevisiae</i> Ulp1
YEASTGP:ULP2	<i>S. cerevisiae</i> Ulp1
SW_HUM:SEN1_HUMAN	<i>H. sapiens</i> SENP1
SW_HUM:SEN2_HUMAN	<i>H. sapiens</i> SENP2
SW_HUM:SEN3_HUMAN	<i>H. sapiens</i> SENP3
SW_HUM:SEN5_HUMAN	<i>H. sapiens</i> SENP5
SW_HUM:SEN6_HUMAN	<i>H. sapiens</i> SENP6
SW_HUM:SEN7_HUMAN	<i>H. sapiens</i> SENP7
SW_HUM:SEN8_HUMAN	<i>H. sapiens</i> SENP8
PF02902	Pfam Ulp1_C (SENP family)
1euv.pdb	Yeast Ulp1-Smt3 X-ray structure
PF00443	Pfam Ubiquitin carboxyl-terminal hydrolase (UCH family)
SW_HUM:UBL3_HUMAN (P15374)	<i>H. sapiens</i> Ubiquitin carboxyl-terminal hydrolase isozyme L3
SW_HUM:UBL1_HUMAN (P09936)	<i>H. sapiens</i> Ubiquitin carboxyl-terminal hydrolase isozyme L1
SW_HUM:UBL5_HUMAN (Q9y5k5)	<i>H. sapiens</i> Ubiquitin carboxyl-terminal hydrolase isozyme L5
1uch.pdb	<i>H. sapiens</i> UCH-L3 X-ray structure
1cmx.pdb	Yeast UCH-ubiquitin aldehyde X-ray structure
SW_HUM:SM33_HUMAN	<i>H. sapiens</i> SUMO-1
SW_HUM:SM32_HUMAN	<i>H. sapiens</i> SUMO-? ( <i>Sentrin 2</i> )
SW_HUM:SM31_HUMAN	<i>H. sapiens</i> SUMO-?
YEASTGP:SMT3	<i>S. cerevisiae</i> Smt3
SW_HUM:UBIQ_HUMAN	<i>H. sapiens</i> Ubiquitin
PF00240	Pfam Ubiquitin family
1a5r.pdb	NMR Structure of <i>H. sapiens</i> SUMO-1 (Sm33)

- 70 -

**Table 2:** Sequence Similarity/Identity Matrix for *H. sapiens* Sm (SUMO) and *S. cerevisiae* Smt3.

e.g.: Sm31 and Sm32 have 98.94% similarity and 96.81% identity.

5		s	s	s	1	1	u	
		m	m	m	a	e	b	
		3	3	3	5	u	i	
		1	2	3	r	v	q	
10		—	—	—			—	
		h	h	h			h	
		u	u	u			u	
		m	m	m			m	
		a	a	a			a	
		n	n	n			n	
15								
	sm31_human		96.81	48.96	48.96	48.10	15.79	3 gaps
	sm32_human	98.94		50.00	50.00	46.84	15.79	3 gaps
	sm33_human	65.62	64.89		100.00	50.63	18.42	3 gaps
	1a5r	65.62	64.89	100.00		50.63	18.42	2 gaps
20	1euv	62.03	63.29	65.82	65.82		13.33	4 gaps
	ubiq_human	39.47	39.47	42.11	42.11	37.33		2 gaps

SUMOylation is a dynamic, reversible process. The cleavage of SUMO from its target (deSUMOylation) is catalyzed by cysteine proteases termed ULP (for Ubiquitin-like proteases) in yeast and SENPs or SUSPs in human (for sentrin/SUMO-specific proteases) (Li, S.J. and M. Hochstrasser, *Nature* 398 (1999) 246-251; Bailey, D. and P. O'Hare, *J Biol Chem* 279 (2004) 692-703). Two ULPs have been identified in yeast (Ulp1 and Ulp2) and at least seven SENPs in human (see Table 1). These proteases play a dual role in the SUMOylation pathway: C-terminal tail processing to generate the di-Glycine motif and de-conjugation by hydrolysis of the Gly-Lys isopeptide bond. They do not cleave ubiquitin isopeptide bonds. In yeast, the deconjugating function of Ulp1 is essential (Li, S.J. and M. Hochstrasser, *Nature* 398 (1999) 246-251). It is reasonable to speculate that the various distinct SENPs in mammals have evolved to work with the distinct SUMO forms. Additionally, sub-cellular localization places a physiologically significant restraint on SUMO isopeptidase specificity. For example, SENP1 can deconjugate SUMO-1 from Ran GAP1 *in vitro*, but not *in vivo*. This is attributed to the fact that Ran GAP1 is attached to the cytoplasmic fibrils of the nuclear pore complex, while SENP1 is localized to the nucleus (Gong, L., *et al.*, *J Biol Chem* 275 (2000) 3355-3359). A nuclear localization signal (NLS1) is found in SENP1 at position 171-177.

An alignment of the seven human SENP and two ULP sequences indicates that there is conservation among the core C-terminal catalytic domain (residues 420-643 in SENP1; see Table 3) which possesses the absolutely conserved Cys, His, and Asp residues that form the catalytic triad and a Gln that forms the oxyanion hole in the active site (Gong, L., *et al.*, *J Biol Chem* 275 (2000) 3355-3359). The variable N-terminal domain is believed to play a regulatory role since expression of the C-terminal catalytic domain alone leads to lower levels of SUMO-1, indicative of constitutive catalytic activity (Bailey, D. and P. O'Hare, *J Biol Chem* 279 (2004) 692-703).

10

**Table 3: Sequence Similarity/Identity (lower/upper) Matrix for *H. sapiens* SENP and *S. cerevisiae* ULP families. e.g.: SENP1 and SENP2 have 73.71% similarity and 60.3% identity.**

15

20

25

30

35

40

45

	s e n p 1	s e n p 2	s e n p 3	s e n p 5	s e n p 6	s e n p 7	s e n p 8	u l p 2	1 e u v
	—	—	—	—	—	—	—	—	—
	h u m a n	h u m a n	h u m a n	h u m a n	h u m a n	h u m a n	h u m a n	e a s t	
senp1_huma		60.31	43.62	43.62	30.21	31.41	21.79	27.03	37.57
24 gaps									
senp2_huma	73.71		37.23	36.17	30.73	30.37	20.11	27.57	35.84
23 gaps									
senp3_huma	65.96	56.38		62.18	29.79	26.74	22.29	27.07	27.75
23 gaps									
senp5_huma	62.23	55.85	76.68		31.91	30.11	22.29	25.56	28.32
24 gaps									
senp6_huma	56.77	52.08	52.66	54.79		57.43	24.86	29.63	29.94
14 gaps									
senp7_huma	53.93	50.26	48.13	52.15	72.28		22.95	29.26	31.43
17 gaps									
senp8_huma	40.22	36.87	44.00	39.43	44.32	46.45		21.71	21.39
18 gaps									
ulp2_yeast	50.81	45.41	51.38	46.67	54.50	50.00	40.00		30.99
15 gaps									
1euv	54.34	54.91	46.24	46.82	48.02	51.43	38.73	47.95	
19 gaps									

The structure of a complex between yeast Ulp1 and Smt3 has been solved (*see*, e.g., Mossessova, E. and C.D. Lima, *Mol Cell* 5 (2000) 865-876). This structure and the sequence alignments described above were used to generate homology models of human SENP1 and SUMO-1 using Moloc (Gerber, P.R. and K. Muller, *J*

- 72 -

*Comput Aided Mol Des* 9 (1995) 251-268). The interactions observed in the active site of the modeled human SENP1 with the SUMO-1 substrate are very similar in the experimental yeast and modeled human structures (see Table 4). There are multiple hydrogen bonds involving the Glu93 and Gln94 residues of SUMO-1, but very little interaction with Thr95. Table 4 also lists the homologous residues in other members of the SENP family and makes a prediction about whether these hydrogen bond interactions with Glu93-Gln94 are preserved. Based on this analysis, very little cross reactivity is predicted for SUMO-1 with other members of the SENP family since two of the four critical hydrogen bonds are missing. Specifically, this analysis indicates that an EQTGG substrate/inhibitor would be highly specific for SENP1 and Ulp1 and would not crossreact with other members of the human sentrin/SUMO-specific protease family. Thus, in some embodiments, the SENP1 antagonists of the invention comprise the sequence EQTGG, or mimetics thereof.

15

**Table 4:** Hydrogen Bond Interactions of homology modeled SENP1/SUMO-1 complex with -EQTGG partial sequence of substrate/proposed inhibitor. Bold text indicates that the H-bond interaction is preserved with this residue.

SENP1 residue	N467	K455	T499	T495
Interaction details (SENP1res:atom-SUMOres:atom)	N467:Nδ2-E93:Oε1	K455:Nζ-E93:Oε2	T499:Oδ1-Q94:Nε2	T495:Oδ1-Q94:Oε1
SENP2 residue	<b>N412</b>	G400	P444	<b>T440</b>
SENP3 residue	<b>N403</b>	D391	D431	<b>S427</b>
SENP5 residue	<b>N584</b>	D572	R612	<b>S608</b>
SENP6 residue	<b>N683</b>	E671	K716	<b>S712</b>
SENP7 residue	<b>N711</b>	E699	K744	<b>S740</b>
SENP8 residue	<b>N28</b>	S16	Q60	P56
Ulp1 residue	<b>N450</b>	<b>R438</b>	<b>T477</b>	<b>S473</b>

20

As described above, in view of this information there are several approaches to develop an inhibitor for SENP1. In some embodiments, since the structures are available both for human SUMO-1 (C-terminal domain, NMR (Bayer, P., *et al. J Mol Biol.* 280 (1998) 275-286) and for the yeast homolog of the SENP1/SUMO-1 complex (X-ray (Mossessova, E. and C.D. Lima, *Mol Cell* 5 (2000) 865-876), one of skill in the art may perform structure-based inhibitor design as well as perform virtual screening of compounds for a predicted inhibitory effect.

25

- 73 -

In some embodiments, the SENP1 antagonists of the invention comprise an aldehyde. Aldehydes are potent inhibitors of cysteine proteases because they form thiohemiacetals. These stable covalent adducts mimic the transition state.

5 Examples in which aldehydes have been used to elucidate the mechanism of cysteine proteases include papain (Schroder, E., et al., *FEBS Lett*, 315 (1993) 38-42) and ubiquitin carboxyl-terminal hydrolase (Pickart, C.M. and I.A. Rose, *J Biol Chem* 261 (1986) 10210-10217). Reduction of the Smt3 substrate by NaBH<sub>4</sub> to the C-terminal aldehyde was used to generate a stable transition state analog for cocrystalization studies with yeast Ulp1 (Mossessova, E. and C.D. Lima, *Mol Cell* 10 5 (2000) 865-876). Therefore, a Gly-Gly aldehyde could serve as a potent inhibitor of the SENP1 cysteine protease.

The three amino acids upstream to the C-terminal Gly-Gly of SUMO-1 (Glu-Gln-Thr), or a mimetic thereof, may be utilized in an inhibitor since these residues contribute significantly to the specificity of the SENP1/SUMO-1 interaction (Table 15 4 and Table 5). Although Thr95 does not interact strongly with SENP1, it provides the proper spacing between the scissile peptide bond and Glu93-Gln95 residues.

**Table 5:** C-terminal sequence of the three SUMO proteins from *H. sapiens*. The sequence corresponding to x1-x3 in Figure 3 is underlined; the di-Glycine motif is in bold.

Sm31	TIDVF <u>QQQT</u> <b>GG</b> VPESLAGHSF
Sm32	TIDVF <u>QQQT</u> <b>GG</b> VY
25 Sm33	VIEVY <u>QEQT</u> <b>GG</b> HSTV
Smt3	IIEAHRE <u>QI</u> <b>GG</b> ATY

Although the structure of the SENP1/SUMO-1 complex indicates that the lysine and its flanking residues of the target protein do not interact with SENP1, an 30 alternative inhibitor design could include these amino acids or moieties to mimic their functional groups.

One possible means to validate specificity is to virtually screen for binding of the proposed SENP1 inhibitor to a family of proteins highly related to SENP1 in structure, function and mechanism, such as ubiquitin carboxyl-terminal hydrolases 35 (Pfam motif UCH; PF00443). A search of the Swissprot database reveals three sequences belonging to the UCH family in humans (Table 1). The structure of

- 74 -

several UCHs have been solved, including the human UCH-L3 isozyme (Johnston, S.C., *et al.*, *Embo J*, 16(13):3787-96 (1997)) and the yeast enzyme in complex with ubiquitin C-terminal aldehyde (Johnston, S.C., *et al.*, *Embo J*. 18 (1999) 3877-3887). Homology models for the other family members could be constructed using these X-ray structures as a template. A highly specific inhibitor of SENP1 inhibitor would interact favorably with SENP1, but not with any UCH. Thus, in some embodiments, the screening methods of the invention further comprises selecting an agent that binds and/or inhibits SENP1 but does not inhibit at least one ubiquitin carboxyl-terminal hydrolase.

5 The nuclear localization of SENP1 plays a role in its substrate specificity. Therefore, in some embodiments, to ensure minimal cross reactivity of the proposed inhibitor with other cysteine proteases, one may utilize SENP1's own nuclear localization sequence (NLS1; PKKTQRR) as part of the inhibitor in a Trojan Horse design. This heptapeptide sequence, when modeled onto the SUMO-1 structure of the SENP1-SUMO1 homology modeled complex, shows only one steric overlap involving Inhibitor Arg6' with SENP1 Lys500. However, there would be sufficient space for the heptapeptide to make conformational adjustments in order to avoid such unfavorable steric or charge interactions since the first 92 amino acids of SUMO-1 would be missing. Accordingly, in some cases, an inhibitor of SENP1 comprises one or more of the following: 1) a Gly Gly aldehyde, 2) the Glu-Gln-Thr sequence, or a mimetic thereof, and/or 3) a nuclear localization signal such as PKKTQRR.

#### ***IX. Pharmaceutical Compositions and Administration***

25 Antagonists of SENP1 can be administered directly to the mammalian subject for treating cancers, including, e.g., bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer. Administration may be by any of the routes normally used for introducing a chemotherapeutic or other anti-cancer drug into ultimate contact with the tissue to be treated. Although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route. SENP1 antagonists may be administered to

- 75 -

an individual either as the sole active ingredient or in combination with chemotherapeutic or other anti-cancer agents.

Therefore, it is an object of the invention to provide a pharmaceutical composition comprising an antagonist of SENP1 and a pharmaceutically acceptable carrier. In

5 another embodiment of the invention, an antagonist of SENP1 is provided for use in medicine. In another embodiment of the invention, an antagonist of SENP1 is used in the manufacture of a medicament or for manufacturing a medicament for the treatment of cancer, in particular breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.

10 Particularly preferred is bladder cancer.

The pharmaceutical compositions of the invention may comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a

15 wide variety of suitable formulations of pharmaceutical compositions of the present invention (*see, e.g., Remington's Pharmaceutical Sciences*, 17<sup>th</sup> ed. 1985)).

The SENP1 antagonists, alone or in combination with other suitable components, can be made into aerosol formulations (*i.e.*, they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized

20 acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic, and aqueous and

25 non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, orally, nasally, topically, intravenously, intraperitoneally, or intrathecally. The formulations of antagonists can be presented in unit-dose or multi-dose sealed containers, such as ampoules

30 and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The antagonists can also be administered as part a of prepared food or drug.

- 76 -

The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial response in the subject over time. The optimal dose level for any patient will depend on a variety of factors including the efficacy of the specific antagonist employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of a particular disease. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular compound or vector in a particular subject.

In determining the effective amount of the antagonist to be administered a physician may evaluate circulating plasma levels of the antagonist, antagonist toxicity, and the production of anti-antagonist antibodies. In general, the dose equivalent of a antagonist is from about 1 ng/kg to 10 mg/kg for a typical subject. Administration can be accomplished via single or divided doses.

#### EXAMPLES

##### **Example 1: Association of SENP1/telomerase expression with bladder cancer**

Our work shows that an increased level of the sentrin/SUMO-specific protease (SENP1) mRNA is present in the urine sediment of bladder cancer patients, who have tumors that do not express measurable telomerase (TERT) mRNA in the urine sediment. Thus, measurement of SENP1 can be used to diagnose, monitor and assess prognosis of cancers, particularly, though not necessarily exclusively, in cases where TERT is not expressed.

Our current work shows that an increase in expression of SENP1 mRNA is associated with cells from tumors not expressing detectable levels of telomerase mRNA. To the best of our knowledge, this is the first demonstration that SENP1 is elevated in telomerase-negative samples from cancer patients. In this context, SENP1 provides a useful marker in diagnostic, monitoring and prognostic tests for cancer. Also, it is worth noting that the expression of telomerase in tumors does not necessarily preclude the overexpression of SENP1. Therefore, overexpression of SENP1 is a useful marker for detection of some tumors that are telomerase positive.

- 77 -

Urine (100 ml) was obtained from human subjects who were healthy or were diagnosed with bladder cancer. Cells from these samples were collected by low speed centrifugation (700 x g for 10 minutes), and rinsed twice with phosphate buffered saline. Cells were lysed in lysis buffer provided in the Roche HighPure total RNA kit. Total RNA was purified using the Roche HighPure total RNA kit. Samples were assayed by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) for expression of the gene encoding telomerase reverse transcriptase (TERT), and expression of protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA), a gene used to monitor the yield of RNA from the samples.

For the current study, nineteen telomerase-negative samples from bladder cancer patients and nineteen telomerase-negative samples from healthy subjects were analyzed by quantitative real-time RT-PCR. Experimental conditions were as follows in each assay: 100 µl reactions contained 50 mM bicine, pH 8.0, 115 mM potassium acetate, 8% glycerol, 3 mM manganese acetate, 200 uM each deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate, and 500 uM of deoxyuridine triphosphate, 2 Units of uracil N-glycosylase (UNG) from Applied Biosystems, 10 Units of r*Tth* DNA polymerase (recombinant form of DNA polymerase from *Thermus thermophilus* from Applied Biosystems), 10 nM 5' nuclease probe, 200 nM each primer, forward and reverse. SENP1 RNA was reverse transcribed, amplified and detected with a fluorescently-labeled probe.

Assays were run in the ABI Prism 7700 with cycling conditions as follows: An initial incubation step at 50°C for 2 minutes to allow UNG-mediated elimination of any contamination by carryover PCR product, denaturation for 1 minute at 95°C, and a reverse transcription step of 30 minutes at 60°C, were followed by 50 cycles of denaturation at 95°C for 20 seconds and annealing/extension at 60°C for 40 seconds. It is worth noting that these fixed assay conditions are arbitrary and that the same results could be obtained with a variety of buffers, salts, glycerol/ DMSO concentrations, nucleotide concentrations, primer and probe concentrations, reverse transcriptases, DNA polymerase enzymes, two-enzyme/one-tube or two-enzyme/two-tube methods for RT-PCR, with and without UNG, using magnesium

- 78 -

or manganese as the divalent cation, various primer / probe concentrations, sequences and thermocycling conditions. Sequences of primers and probes were as follows: For SENP1 CAAGAAGTGCAGCTTATAATCCAA (SEQ ID NO:6; forward "sense" primer) and GTCTTTCGGGTTTCGAGGTAA (SEQ ID NO:7; reverse "antisense" primer), CTCAGACAGTTTTCTTGGCTCAGGCG (SEQ ID NO:8; probe); for PPP1CA GAGCACACCAGGTGGTAGAA (SEQ ID NO:9; forward primer), GGGCTTGAGGATCTGGAAA (SEQ ID NO:10; reverse primer), GAGTTTGACAATGCTGGCGCCATGATGAGT (SEQ ID NO:11; probe).

Levels of SENP1 mRNA were measured by quantitative real-time RT-PCR. Relative copy numbers of SENP1 were determined based on RNA quantification standards. These standards consist of PPP1CA run-off transcripts of known concentrations, reverse transcribed and amplified by PCR under the same conditions as the experimental samples. Cycle threshold (Ct) values were calculated to provide a measure of the amount of mRNA that was present at the beginning of the amplification reaction. Since efficiencies in amplification reactions are rarely, if ever, exactly the same with different primer / probe sets or in standards versus samples from human subjects due to the possible presence of inhibitors of reverse transcription that might carry through the sample preparation in the latter case, copy numbers are stated as relative copies of a given transcript in a sample rather than as an absolute copy number.

As shown in Table I, the median number of copies of SENP1 in healthy subjects is 4, the median in bladder cancer telomerase-negative patients is 1899 copies. The median is calculated rather than the mean in order to mitigate the effect of outliers on calculations. The receiver-operator characteristic curve for these samples (Figure1) (as determined according to the methods of Agresti, A., Categorical Data Analysis, pp. 228-230 (2002)) shows that the telomerase-negative bladder cancer patients can be distinguished from the telomerase-negative healthy subjects on the basis of SENP1. To a first approximation this subset of patients can be distinguished from one another with a 100% sensitivity and a 90% specificity.

**Table I:** Relative copies of SENP1 mRNA in healthy subjects vs. telomerase negative bladder cancer patients

Bladder Cancer Patients- Telomerase Negative	Healthy Subjects
SENP1 Copies	SENP1 Copies
125	0
201	0
240	0
304	0
322	0
655	0
1184	0
1413	0
1499	3
1899	4
2708	4
2873	5
4113	10
4610	10
5188	12
5839	21
6195	26
9941	380
14173	1675

Median	1899	4
--------	------	---

This data can also be normalized to the level of a housekeeping gene present in each sample. Such normalization controls for variations in the number of cells in the initial sample, any RNA degradation, or the presence of inhibitors in a sample. In this case, the level of PPP1CA previously measured, under the same conditions, was used for normalization. Calculations were as follows: The relative number of copies of SENP1 mRNA in a given sample was divided by the relative number of copies of PPP1CA mRNA in the same sample. For ease of manipulation and recording, this number was multiplied by  $1 \times 10^5$ . Thus, the normalized copy number for SENP1 mRNA shown in Table II represents the number of copies of SENP1 mRNA per  $1 \times 10^5$  copies of PPP1CA mRNA. The median normalized copy number for SENP1 mRNA in healthy subjects is 1096, the median in bladder cancer telomerase-negative patients is 11994. The receiver-operator characteristic

- 80 -

curve for these data (Figure 2) shows that the telomerase-negative bladder cancer patients can be distinguished from the telomerase-negative healthy subjects on the basis of SENP1. To a first approximation this subset of patients can be distinguished from one another with a sensitivity of 90% and a specificity of 70%.

5

**Table II:** Relative copies of SENP1 mRNA normalized to levels of the housekeeping gene PPP1CA in healthy subjects vs. telomerase negative bladder cancer patients

Bladder Cancer Patients- Telomerase Negative	Healthy Subjects
SENP1 Copies	SENP1 Copies
2017	0
2344	0
3242	0
3379	0
3509	0
5095	0
6892	0
8182	0
10413	137
11994	1096
15370	1445
16401	1592
17827	2257
22070	3688
22378	4561
23384	7639
26195	10591
33182	19453
76298	47093

Median	11994	1096
--------	-------	------

Our results indicate that SENP1 can be used as a marker to differentiate cancer patients from healthy patients on the basis of mRNA found in cells in samples from the patients.

10

- 81 -

**Example 2: Association of SENP1 and/or telomerase expression with breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer**

100 mg of frozen solid tissues were homogenized in 7.5 ml of Ultraspec solution  
5 (Biotexc) for 30 seconds. Total RNA was extracted using the Biotecx Ultraspec ®  
RNA kit. RNA was further purified using the QIAGEN RNeasy mini kit. (for a  
maximum of 100 ug of total RNA), including a QIAGEN DNase treatment.  
cDNA was synthesized using 3-50 ug of total RNA per reaction, based on the  
method described in the Invitrogen Superscript™ Double-Strand cDNA synthesis  
10 kit. Reagents were purchased from Invitrogen unless otherwise stated. In the first  
strand synthesis reaction, the final concentrations of reagents was as follows: 5 pM  
Poly dT primer (Affymetrix #900375), 1X First Strand Buffer, 0.01M DTT, 0.5  
mM each of dATP, dCTP, dGTP and dTTP, 400 Units of SuperScript™ II RNase  
H-Reverse Transcriptase (SSRT), total reaction volume was 20 µl. First strand  
15 primer (1 µl) was incubated with total RNA (plus RNase free water to bring  
volume to 10 µl) at 70°C for 10 min., followed by incubation on ice for 2 min.  
First Strand Buffer, DTT and dNTPs were added followed by incubation at 42°C  
for 2 min. After addition of SSRT II samples were incubated for 1 hr at 42°C.  
Second strand synthesis was then performed. To the entire 20 µl reaction from first  
20 strand synthesis the following reagents were added to the final concentrations  
indicated: 1X Second Strand buffer, 0.2 mM each of dATP, dCTP, dGTP, and  
dTTP, 10 U of E. coli DNA Ligase, 40 U of E. Coli DNA Polymerase I, 2 U of  
RNase H, 20 U of T4 DNA Polymerase, total reaction volume was 150 µl. All  
reagents except the T4 DNA Polymerase were mixed and incubated for 2 hr at  
25 16°C. T4 DNA Pol was then added followed by a 16°C incubation for 5 min.  
For each sample the entire 150 µl of resulting ds cDNA was purified by use of  
Phase Lock Gel (available through Brinkmann) as follows: 150 ul of ds cDNA was  
mixed with an equal volume of phenol-chloroform-isoamyl alcohol. The aqueous  
phase was transferred to a new tube and the RNA was precipitated by standard  
30 methods using ammonium acetate and ethanol, followed by two washes with ice  
cold 100 % ethanol. The pellet was dried and resuspended in 2-10 ul of RNase free  
deionized water. cDNA was quantitated by measuring the OD260.

- 82 -

Quantitative PCR was run on samples under the following conditions: 7 ng of cDNA, 1X TaqMan® Universal Master Mix (purchased stock available from Applied Biosystems was considered 2X), 2.4 µM each forward and reverse human GAPDH primers, and 0.5 uM human GAPDH TaqMan probe, and the primers and probe for a given gene of interest was added to the same reaction tube at concentrations described for GAPDH primers and probes. Sequences of these primers and probes were: For SENP1, CAAGAAGTGCAGCTTATAATCCAA (forward “sense” primer) and GTCTTTCGGGTTTCGAGGTAA (reverse “antisense” primer), CTCAGACAGTTTTCTTGGCTCAGGCG (TaqMan probe); for TERT, TGGGCACGTCCGCA (forward), GGCGTGGTGGCACATGAA (reverse), TCATCGAGCAGAGCTCCTCCCTGAATGAGG (TaqMan probe). All primers and probes, including those for a panel of seven housekeeping genes (see below) were purchased from ABI. Total volume of each assay was 20 µl. Cycling was performed on an ABI Prism® 7900 HT Sequence Detection System. An initial incubation of 2 minutes at 50°C was followed by 10 minutes at 95°C then 40-55 cycles of 95°C for 15 sec and 60°C for 1 min. Relative expression levels of SENP1 and TERT mRNA (referred to as genes of interest or GOI) were calculated in the following way: Cycle threshold (Ct) values were determined from RT-PCR for SENP1 and TERT, GAPDH and a panel of seven “housekeeping” human genes. The seven genes were hypoxanthine phosphoribosyl transferase, β-glucuronidase, β2-microglobulin, phosphoglyceratekinase, cyclophilin, β-actin, and large ribosomal protein PO. Based on the Cts of the panel of housekeeping genes, the GAPDH Ct was adjusted to give the expected value. This adjustment compensates for any small unexpected differences in the GAPDH Ct that could be explained by GAPDH not behaving as the “average” housekeeping gene in a particular sample. The relative expression level of the GOI is then calculated as:

$$\text{Ct}(\text{adjusted GAPDH}) - \text{Ct}(\text{GOI}) = \Delta\text{Ct}$$

$$2^{\Delta\text{Ct}} = \text{relative expression level of GOI}$$

As shown in Figures 3 through 11 and in Table III, our current data shows that in a variety of cancers some, but not all, tumors show telomerase (TERT) expression

- 83 -

elevated above that in normal cells. Likewise, some tumors, but not all, show an increase in SENP1 expression. Use of both SENP1 and TERT in combination as molecular markers for cancer allows for a greater number of samples from tumor tissue to be identified as cancer positive than use of either marker alone. Thus, a

5 molecular assay in which the up-regulation of either marker was scored as positive for cancer would show an increased sensitivity for cancer detection. This increased sensitivity would, not surprisingly, come at a cost of a somewhat decreased specificity (i.e. an increased number of subjects who did not have cancer would be identified as having cancer). To use an assay for a given diagnostic setting, one

10 would choose standardized values for positive and negative calls that would maximize correct calls, thus maximizing sensitivity and specificity. In the examples shown, threshold values were chosen that, for each individual marker, would give approximately 80% specificity. Unless otherwise shown, the threshold for detection of TERT is zero.

15 Table III provides a summary of performance of telomerase and senp1 as single markers or as combined markers. Sensitivity is the number of cancer positive samples of a given tissue type that are called cancer positive divided by the total number of cancer positive samples of that tissue type. Specificity is the number of cancer negative (or normal) samples of a given tissue type that are called cancer

20 negative divided by the total number of cancer negative samples of that tissue type. The "accuracy" of a given assay is defined as the sum of its sensitivity and specificity.

Table III

Cancer Type	Telomerase			SENP1			Combined		
	Sensitivity	Specificity	Accuracy	Sensitivity	Specificity	Accuracy	Sensitivity	Specificity	Accuracy
Bladder	3/4 75%	7/8 87%	162%	2/4 50%	8/8 100%	150%	4/4 100%	7/8 87%	187%
Breast	7/11 63%	7/7 100%	163%	1/11 9%	6/7 85%	94%	8/11 72%	6/7 85%	157%
Colon	9/54 16%	14/17 82%	98%	14/54 26%	14/17 82%	108%	21/54 38%	13/17 76%	114%
Kidney	0/7 0%	5/5 100%	100%	4/7 57%	5/5 100%	157%	4/7 57%	5/5 100%	157%
Lung	3/14 21%	20/21 95%	116%	5/14 36%	17/21 80%	116%	7/14 50%	16/21 76%	126%
Ovarian	0/3 0%	4/5 80%	80%	1/3 33%	4/5 80%	113%	1/3 33%	3/5 60%	93%
Pancreatic	1/6 16%	1/1 100%	116%	3/6 50%	1/1 100%	150%	4/6 66%	1/1 100%	166%
Pancreatic (2nd set)	2/9 22%	10/10 100%	122%	4/9 44%	9/10 90%	134%	5/9 56%	9/10 90%	146%
Pancreatic (metastatic)	5/6 83%			1/6 17%			5/6 83%		
Small Intestine	0/2 0%	7/8 87%	87%	2/2 100%	7/8 87%	187%	2/2 100%	7/8 87%	187%
FOR ALL CANCERS	30/116 26%	75/82 91%	117%	36/116 31%	71/82 87%	118%	59/116 51%	67/82 82%	133%

- 85 -

5 It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

List of References

- Agresti, A., *Categorical Data Analysis*, pp. 228-230, 2002
- Akerstrom *et al.*, *J. Immunol.* 135 (1985) 2589-2542
- Alderton *et al.*, *Anal. Biochem.* 201 (1992) 166-169
- 5 Altschul *et al.*, *J. Mol. Biol.* 215 (1990) 403-410
- Altschul *et al.*, *Nuc. Acids Res.* 25 (1977) 3389-3402
- Angelopoulou *et al.*, *Anticancer Res.* 23 (2003) 4821-4829
- Arnold *et al.*, *Clin. Chem.* 35 (1989) 1588-1594
- Asai (ed.), *Methods in Cell Biology: Antibodies in Cell Biology*, Vol. 37, 1993
- 10 Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, 2002
- Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1995 Supplement
- Bacchetti, S. and Counter, C.M. *Int. J. Oncology* 7 (1995) 423-432
- Bailey *et al.*, *J Biol Chem.* 279 (2004) 692-703
- Bates *et al.*, *Mol. Plant Pathol.* 2 (2001) 275-280
- 15 Baum C&EN, Jan 18, page 33 (1993)
- Bayer, P., *et al.*, *J Mol Biol.* 280 (1998) 275-286
- Bodnar, A.G., *et al.*, *Science* 279 (1998) 349-352
- Bryan, T.M., *Hum Mol Genet* 6 (1997) 921-926
- Bryan, T.M., *Nature Medicine* 3 (1997) 1271-1274
- 20 Campbell *et al.*, *J. Org. Chem.* 59 (1994) 658
- Capaldi *et al.*, *Nucleic. Acids Res.*, 28 (2000) 21e
- Chen *et al.*, *Biotechniques* 35 (2003) 158-162
- Chen *et al.*, *J. Amer. Chem. Soc.* 116 (1994) 2661
- Cho *et al.*, *Science* 261 (1993) 1303
- 25 Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, pp. 77-96, 1985
- Coligan, *Current Protocols in Immunology*, 1991
- Collins, K., *Curr. Opin Cell Biol.* 12 (2000) 378-383
- Compton, *Nature* 350 (1991) 91-92
- Cong, Y.S., *et al.*, *Microbiol. Mol. Biol. Rev.* 66 (2002) 407-425
- 30 De Lange, T., *Science* 279 (1998) 334-335
- DeGraves, *et al.*, *Biotechniques* 34 (2003) 106-110, 112-115
- Deiman B. *et al.*, *Mol Biotechnol.* 20 (2002) 163-179
- DeVita, V.T., *et al.* (eds.), *Cancer: Principles and Practice*, 1997
- Dunham, M.A. *et al.*, *Nature Genetics* 26 (2000) 447-450
- 35 Eagle *et al.*, *J. Exp. Med.* 131 (1970) 836-879
- Folkman, *Angiogenesis and Cancer, Sem Cancer Biol.I*, 1992

- Freshney *Anticancer Res.* 5 (1985) 111-130  
Freshney, *Culture of Animal Cells a Manual of Basic Technique*, 3<sup>rd</sup> ed., 1994  
Furka, *Int. J. Pept. Prot. Res.* 37 (1991) 487-493  
Gerber, P.R. and K. Muller, *J Comput Aided Mol Des* 9 (1995) 251-268  
5 Gibson *et al.*, *Genome Research* 6 (1996) 995-1001  
Goding, *Monoclonal Antibodies: Principles and Practice*, 2<sup>nd</sup> ed., 1986  
Gong *et al.*, *J Biol Chem.* 275 (2000) 3355-3359  
Gong, L., *et al.*, *FEBS Lett* 448 (1999) 185-189  
Greiden *et al.*, *Nature* 337 (1989) 331  
10 Guilleret, I. *et al.*, *Carcinogenesis* 23 (2002) 2025-2030  
Gullino, *Angiogenesis, tumor vascularization, and potential interference with  
tumor growth.* in *Biological Responses in Cancer*, Mihich (ed.)  
pp. 178-184, 1985  
Hagihara *et al.*, *J. Amer. Chem. Soc.* 114 (1992) 6568  
15 Hanahan and Weinberg, *Cell* 100 (2000) 57-70  
Harlow & Lane, *Antibodies, A Laboratory Manual*, 1988  
Hatch *et al.*, *Genet. Anal.* 15 (1999) 35-40  
Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89 (1989) 10915  
Hirschmann *et al.*, *J. Amer. Chem. Soc.* 114 (1992) 9217-9218  
20 Hiyama *et al.*, *Cancer Lett.* 194 (2003) 221-233  
Hobbs *et al.*, *Proc. Nat. Acad. Sci. USA* 90 (1993) 6909-6913  
Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88 (1991) 7276-7280  
Houghton *et al.*, *Nature* 354 (1991) 84-88  
Huse *et al.*, *Science* 246 (1989) 1275-1281  
25 Innis *et al.* (eds.), *PCR Protocols. A Guide to Methods and Applications*, 1990  
Iqbal *et al.*, *Mol. Cell Probes* 13 (1999) 315-320  
Jakobi *et al.*, *Anal. Biochem.* 175 (1988) 196-201  
Johnson, E.S., *et al.*, *Embo J* 16 (1997) 5509-5519  
Johnston, S.C., *et al.*, *Embo J.* 18 (1999) 3877-3887  
30 Karlin and Altschul, *Proc. Natl. Acad. Sci. USA* 90 (1993) 5873-5787  
Kievits *et al.*, *J. Virol. Methods* 35 (1991) 273-286  
Kim, N.W. *et al.* *Science* 266 (1994) 2011-2015  
Klostermeier and Millar, *Biopolymers* 61 (2002) 159-179  
Kohler and Milstein, *Nature* 256 (1975) 495-497  
35 Kozbor *et al.*, *Immunology Today* 4 (1983) 72  
Kriegler, *Gene Transfer and Expression: A Laboratory Manual*, 1990

- Kronval *et al.*, *J. Immunol.* 111 (1973) 1401-1406
- Larrick, J. (ed.), *The PCR Technique: Quantitative PCR*, 1997
- Lee *et al.*, *Nucleic Acids Res.* 21 (1993) 3761-3766
- Li, S.J. and M. Hochstrasser, *Nature* 398 (1999) 246-251
- 5 Liang *et al.*, *Science*, 274 (1996) 1520-1522)
- Lipinski *et al.* *Adv Drug Delivery Res* 23 (1997) 3-25
- Lisby, *Mol. Biotechnol.* 12 (1999) 75-99)
- Little *et al.*, *Clin. Chem.* 45 (1999) 777-784
- Lizardi *et al.*, *Bio/Technology* 6 (1988) 1197
- 10 Maggio (ed.), *Enzyme Immunoassay*, 1980
- Marko *et al.*, *Anal. Biochem.* 121 (1982) 382-387
- Marks *et al.*, *Biotechnology* 10 (1992) 779-783
- McCafferty *et al.*, *Nature* 348 (1990) 552-554
- McEachern, M.J., *et al. Annu. Rev. Genet.* 34 (2000) 331-358
- 15 Mehle, C., *et al.*, *Oncogene* 13 (1996) 161-166
- Melissourgos *et al.*, *Urology* 62 (2003) 362-367
- Miller *et al.*, *J. Clin. Microbiol.* 32 (1994) 393-397
- Mossessova, E. and C.D. Lima, *Mol Cell* 5 (2000) 865-876
- Muller, S., *et al.*, *Nat Rev Mol Cell Biol* 2 (2001) 202-210)
- 20 Needleman and Wunsch, *J. Mol. Biol.* 48 (1970) 443
- Nilsen *et al.*, *J. Theoretical Biology* 187 (1997) 273-284
- Paul (ed.), *Fundamental Immunology*, 3<sup>rd</sup> ed., 1993
- PCT/GB91/00212
- PCT/US96/10287
- 25 Pearson and Lipman, *Proc. Nat'l. Acad. Sci. USA* 85 (1988) 2444
- Phyffer, *et al.*, *J. Clin. Microbiol.* 34 (1996) 834-841
- Piatyszek M. A. *et al.*, *Meth. Cell Sci.* 17 (1995) 1-15
- Pickart, C.M. and I.A. Rose, *J Biol Chem* 261 (1986) 10210-10217
- Remington's Pharmaceutical Sciences*, 17<sup>th</sup> ed., 1985
- 30 Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 3<sup>rd</sup> ed., 2001
- Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Vols. 1-3,  
Cold Spring Harbor Press, New York, 1989
- Scheel, C. and Poremba, C. *Virchows Arch* 440 (2002) 573-582
- Schroder, E., *et al.*, *FEBS Lett*, 315 (1993) 38-42
- 35 Shay, J.W. and Bacchetti, S., *Eur. J. Cancer*, 33 (1997) 787-791
- Shippen-Lentz *et al.*, *Science* 247 (1990) 546

- Smith and Waterman, *Adv. Appl. Math.* 2 (1970) 482c  
Stites and Terr (eds.), *Basic and Clinical Immunology*, 7<sup>th</sup> ed., 1991  
Strickland & Beers, *J. Biol. Chem.* 251 (1976) 5694-5702  
Taton *et al.*, *Science* 289(2000) 1757-1760  
5 Temin, *J. Natl. Cancer Inst.* 37 (1966) 167-175  
Thellin, O. *et al.*, *J. Biotechnol.* 75 (1999) 291  
Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, "Overview of principles of hybridization and the strategy of nucleic acid assays", 1993  
10 Tsutsui, T. *et al.*, *Carcinogenesis* 24 (2003) 953-965  
Tyagi and Kramer, *Nature Biotech.* 14 (1996) 303-309  
U.S. Patent Application No. 07/695,072  
Unkless *et al.*, *J. Biol. Chem.* 249 (1974) 4295-4305  
US 2002/0012969  
15 US 2002/0025518  
US 4,366,241  
US 4,376,110  
US 4,517,288  
US 4,683,195  
20 US 4,683,202  
US 4,767,700  
US 4,837,168  
US 4,851,331  
US 4,889,818  
25 US 4,914,210  
US 4,946,778  
US 4,948,882  
US 4,994,373  
US 5,010,175  
30 US 5,079,352  
US 5,102,784  
US 5,118,605  
US 5,118,802  
US 5,119,801  
35 US 5,135,717  
US 5,155,018

- 90 -

US 5,210,015  
US 5,232,829  
US 5,234,809  
US 5,288,514  
5 US 5,294,534  
US 5,312,728  
US 5,352,600  
US 5,405,774  
US 5,424,414  
10 US 5,437,977  
US 5,464,746,  
US 5,466,591  
US 5,487,972  
US 5,491,063  
15 US 5,506,337  
US 5,514,546  
US 5,519,134  
US 5,525,462  
US 5,525,465  
20 US 5,525,735  
US 5,539,083  
US 5,547,861  
US 5,549,974  
US 5,556,959  
25 US 5,569,588  
US 5,571,673  
US 5,593,853  
US 5,595,890  
US 5,597,696  
30 US 5,618,711  
US 5,641,633  
US 5,648,245  
US 5,674,738  
US 5,679,510  
35 US 5,679,785  
US 5,683,872

US 5,683,875  
US 5,707,813  
US 5,710,028  
US 5,714,320  
5 US 5,728,525  
US 5,750,343  
US 5,789,562  
US 5,792,614  
US 5,795,718  
10 US 5,795,762  
US 5,800,989  
US 5,804,375  
US 5,808,036  
US 5,808,044  
15 US 5,814,447  
US 5,837,453  
US 5,844,106  
US 5,846,723  
US 5,846,726  
20 US 5,853,990  
US 5,856,092  
US 5,866,336  
US 5,876,924  
US 5,880,287  
25 US 5,882,867  
US 5,888,723  
US 5,888,739  
US 5,919,630  
US 5,935,791  
30 US 5,945,283  
US 5,955,589  
US 5,958,700  
US 5,972,602  
US 5,981,176  
35 US 5,990,303  
US 5,994,063

US 6,001,611  
US 6,022,686  
US 6,033,854  
US 6,054,279  
5 US 6,080,068  
US 6,110,677  
US 6,121,001  
US 6,124,090  
US 6,130,047  
10 US 6,140,055  
US 6,174,998  
US 6,177,249  
US 6,180,349  
US 6,210,884  
15 US 6,214,979  
US 6,221,603  
US 6,221,604  
US 6,245,514  
US 6,261,779  
20 US 6,261,784  
US 6,268,128  
US 6,294,338  
US 6,312,906  
US 6,320,005  
25 US 6,326,145  
US 6,335,166  
US 6,344,329  
US 6,348,596  
US 6,350,580  
30 US 6,352,827  
US 6,361,944  
US 6,365,724  
US 6,368,803  
US 6,379,888  
35 US 6,383,393  
US 6,383,756

- US 6,391,554  
US 6,399,303  
US 6,399,392  
US 6,406,297  
5 US 6,417,340  
US 6,440,707  
US 6,495,324  
US 6,506,564  
US 6,528,254  
10 US 6,528,632  
US 6,551,774  
US 6,582,964  
US 6,596,527  
US 6,607,898  
15 Vaughn *et al.*, *Nature Biotechnology*, 14 (1996) 309-314  
Vogelstein *et al.*, *Proc. Natl. Acad. Sci. USA* 76 (1979) 615-619  
Vuorinen, *et al.*, *J. Clin. Microbiol.* 33 (1995) 1856-1859  
Walker, *et al.* *Nucleic Acids Res.* 20 (1992) 1691-1696  
Walker, *PCR Methods Appl* 3 (1993) 1-6  
20 Wang *et al.*, *Electroanalysis* 10 (1998) 553-556  
Wang *et al.*, *J. Am. Chem. Soc.* 120 (1998) 8281-8282  
Ward *et al.*, *Nature* 341 (198) 544-546  
Warrington, J.A. *et al.*, *Physiol. Genomics* 2 (2000) 143  
Wege *et al.*, *Nuc. Acids Res.* 31 (2003) e3  
25 Whur *et al.*, *Br. J. Cancer* 42 (1980) 305-312  
Wilson *et al.*, *Harrison's Principles of Internal Medicine*, 12th Edition, McGraw-Hill, Inc., 1991  
WO 01/37291  
WO 91/19735  
30 WO 92/00091  
WO 93/20242  
WO 95/35390

- Woodring *et al.*, *Nuc. Acids Res.* 23 (1995) 3794-3795  
Wu and Brand, *Anal. Biochem.* 218 (1994) 1-13  
Yan, P. *et al.* *Cancer Res.* 59 (1999) 3166-3170  
Yeager, T.R., *et al.*, *Cancer Res.* 59 (1999) 4175-4179  
5 Yeh, E.T., *et al.*, *Gene* 248 (2000) 1-14

PATENT CLAIMS

1. A method of detecting SENP1 expression in a biological sample, the method comprising,  
5 determining the quantity of SENP1 in a biological sample from an individual having or suspected of having a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.
2. The method according to claim 1, wherein the method further comprises obtaining the biological sample from the individual.
- 10 3. The method according to any of the claims 1 to 2, wherein the method further comprises recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.
4. The method according to any of the claims 1 to 3, wherein the quantity of  
15 SENP1 is determined by detecting a polynucleotide encoding SENP1 in the sample.
5. The method according to claim 4, wherein the detection step comprises amplifying the polynucleotide in an amplification reaction.
6. The method according to claim 5, wherein the amplification reaction  
20 comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1.
- 25 7. The method according to any of the claims 5 to 6, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product.
8. The method according to any of the claims 5 to 7, wherein the amplification  
30 reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide.

- 96 -

9. The method according to any of the claims 1 to 8, wherein the method further comprises determining the quantity of telomerase in the biological sample.
10. The method according to claim 9, wherein the method further comprises comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells.
11. A method of detecting SENP1 expression in a biological sample, the method comprising,  
determining the quantity of SENP1 in a biological sample from an individual; and  
recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.
12. The method according to claim 11, wherein the method further comprises obtaining the biological sample from the individual.
13. The method according to any of the claims 11 to 12, wherein the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample.
14. The method according to claim 13, wherein the detection step comprises amplifying the polynucleotide in an amplification reaction.
15. The method according to claim 14, wherein the amplification reaction comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1.
16. The method according to any of the claims 14 to 15, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product.

17. The method according to any of the claims 14 to 16, wherein the amplification reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide.
- 5 18. The method according to any of the claims 11 to 17, wherein the method further comprises determining the quantity of telomerase in the biological sample.
19. The method according to claim 18, wherein the method further comprises comparing the quantity of SENP1 and telomerase in the sample to a SENP1  
10 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells.
20. A method of detecting SENP1 expression in a biological sample, the method comprising,  
15 determining the quantity of SENP1 in a biological sample from an individual, wherein the biological sample is selected from the group consisting of a breast biopsy, a colon biopsy, a kidney biopsy, a lung biopsy, an ovary biopsy, a pancreas biopsy, a small intestine biopsy, a bronchial lavage and a stool.
- 20 21. The method according to claim 20, wherein the method further comprises obtaining the biological sample from the individual.
22. The method according to any of the claims 20 to 21, wherein the method further comprises recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer,  
25 ovarian cancer, pancreatic cancer, and small intestine cancer.
23. The method according to any of the claims 20 to 22, wherein the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample.
24. The method according to claim 23, wherein the detection step comprises  
30 amplifying the polynucleotide in an amplification reaction.
25. The method according to claim 24, wherein the amplification reaction comprises at least two different oligonucleotides comprising a sequence at

- least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1.
- 5        26. The method according to any of the claims 24 to 25, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product.
27. The method according to any of the claims 24 to 26, wherein the amplification reaction comprises a template-dependent nucleic acid
- 10        27. The method according to any of the claims 24 to 26, wherein the amplification reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide.
28. The method according to any of the claims 20 to 27, wherein the method further comprises determining the quantity of telomerase in the biological sample.
- 15        29. The method according to claim 28, wherein the methods further comprise comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells.
- 20        30. A method for identifying an SENP1 antagonist, the method comprising, contacting a plurality of agents to a cell expressing SENP1, wherein the cell does not express telomerase and the cell expresses a neoplastic phenotype, and selecting an agent that inhibits a neoplastic phenotype, thereby identifying an SENP1 antagonist.
- 25        31. The method according to claim 30, wherein the cell does not express TERT.
32. The method according to any of the claims 30 to 31, further comprising testing the effect of the selected agent on cancer cells.
33. A pharmaceutical composition comprising an antagonist of SENP1 and a pharmaceutically acceptable carrier.
- 30        34. Use of an antagonist of SENP1 for manufacturing a medicament for the treatment of cancer.

35. Use according to claim 34, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer.
36. Pharmaceutical composition according to claim 33 or use according to any  
5 of the claims 34 to 35, wherein the antagonist is identified by the steps of: contacting a plurality of agents to a cell expressing SENP1, wherein the cell does not express telomerase and the cell expresses a neoplastic phenotype, and  
selecting an agent that inhibits a neoplastic phenotype, thereby identifying  
10 an SENP1 antagonist.
37. An inhibitor of SENP1 protease activity, wherein the inhibitor comprises an amino acid sequence comprising Glu-Gln-Thr-Gly-Gly, or a mimetic thereof, wherein the final Gly terminates in an aldehyde.
38. The inhibitor according to claim 37, wherein the inhibitor comprises a  
15 nuclear localization signal sequence.
39. The inhibitor according to claim 38, wherein the nuclear localization signal sequence comprises Pro-Lys-Lys-Thr-Gln-Arg-Arg.
40. A method comprising determining the quantity of SENP1 and telomerase in  
20 a biological sample from an individual, wherein the quantity of SENP1 is detected by detecting an RNA encoding SENP1 in the sample.
41. The method according to claim 40, wherein the method further comprises obtaining the biological sample from the individual.
42. The method according to any of the claims 40 to 41, wherein the method further comprises recording a diagnosis of a cancer.
- 25 43. The method according to any of the claims 40 to 42, wherein the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample.
44. The method according to claim 43, wherein the detection step comprises amplifying the polynucleotide in an amplification reaction.
- 30 45. The method according to any of the claims 44, wherein the amplification reaction comprises at least two different oligonucleotides comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ

- 100 -

ID NO:1, or a complement thereof, such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO:1.

- 5
46. The method according to any of the claims 44 to 45, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product.
47. The method according to any of the claims 44 to 46, wherein the amplification reaction comprises a template-dependent nucleic acid polymerase with 5'-3' exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide.
- 10
48. The method according to any of the claims 40 to 47, wherein the method further comprises comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells.
- 15
49. A kit for detecting a cancer cell in a biological sample from an individual, the kit comprising,
- a) at least one oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that when the oligonucleotide and a polynucleotide comprising SEQ ID NO:1 are submitted to an amplification reaction, the oligonucleotide primes amplification of at least a fragment of SEQ ID NO:1;
- 20
- b) a detectably-labeled oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof;
- 25
- c) at least one oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:
- i) human telomerase RNA (TERC);
- 30
- ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- iii) a complement of TERC; or

- 101 -

- iv) a complement of TERT;  
such that when the oligonucleotide and TERC or TERT mRNA are submitted to an amplification reaction, the oligonucleotide primes amplification of at least a fragment of TERC or TERT mRNA; and
- 5 d) a detectably-labeled oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:
- i) human telomerase RNA (TERC);
- ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- 10 iii) a complement of TERC; or
- iv) a complement of TERT.
50. A reaction mixture comprising:
- a) at least one oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof, such that when the oligonucleotide and a
- 15 polynucleotide comprising SEQ ID NO:1 are submitted to an amplification reaction, the oligonucleotide primes amplification of at least a fragment of SEQ ID NO:1;
- b) a detectably-labeled oligonucleotide comprising a sequence at least
- 20 90% identical to at least 10 contiguous nucleotides of SEQ ID NO:1, or a complement thereof
- c) at least one oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:
- i) human telomerase RNA (TERC);
- 25 ii) human telomerase reverse transcriptase protein (TERT) mRNA;
- iii) a complement of TERC; or
- iv) a complement of TERT;
- such that when the oligonucleotide and TERC or TERT mRNA are submitted to an amplification reaction, the oligonucleotide primes
- 30 amplification of at least a fragment of TERC or TERT mRNA; and

- 102 -

- 5
- d) a detectably-labeled oligonucleotide comprising a sequence at least 90% identical to at least 10 contiguous nucleotides of:
- i) human telomerase RNA (TERC);
  - ii) human telomerase reverse transcriptase protein (TERT) mRNA;
  - iii) a complement of TERC; or
  - iv) a complement of TERT.

Figure 1




Figure 2




Figure 3A




Figure 3B




Figure 4A




Figure 4B




Figure 5A




Figure 5B




Figure 6A




Figure 6B




Figure 7A




Figure 7B




Figure 8A




Figure 8B




Figure 9A




Figure 9B




Figure 10A




Figure 10B




Figure 11A





Figure 11B



SEQUENCE LISTING

<110> Roche Diagnostics GmbH  
F. Hoffmann-La Roche AG

<120> SENP1 as a Marker for Cancer

<130> 22347WO

<150> US 60/569,220

<151> 2004-05-06

<150> US 60/599,318

<151> 2004-08-05

<160> 20

<170> PatentIn Ver. 3.2

<210> 1

<211> 1932

<212> DNA

<213> Homo sapiens

<220>

<223> sentrin/SUMO-specific protease 1 (SENP1)

<400> 1

```

atggatgata ttgctgatag gatgaggatg gatgctggag aagtgacttt agtgaaccac 60
aactccgfat tcaaaaccca ctcctgcca caaacagggt ttccagagga ccagctttcg 120
ctttctgacc agcagatfff atcttcagg caaggacatt tggaccgatc ttttacatgt 180
tccacaagaa gtgcagctta taatccaagc tattactcag ataatccttc ctgagacagt 240
tttcttggct cagggcattt aagaaccttt ggccagagtg caaatggcca atggagaaat 300
tctaccccat cgtcaagctc atctttacaa aaatcaagaa acagccgaag tctttacctc 360
gaaacccgaa agacctcaag tggattatca aacagttttg cgggaaagtc aaaccatcac 420
tgccatgtat ctgcatatga aaaatctttt cctattaaac ctgttccaag tccatcttgg 480
agtggttcat gtcgtcgaag tcttttgagc cccaagaaaa ctgagaggcg acatgttagt 540
acagcagaag agacagttca agaagaagaa agagagattt acagacagct gctacagatg 600
gtcacagggg aacagttttac tatagccaaa cccaccacac attttccttt acacctgtct 660
cgatgtctta gttccagtaa aaatactttg aaagactcac tgtttaaaaa tggaaactct 720
tgtgcatctc agatcattgg ctctgatact tcatcatctg gatctgccag cattttaact 780
aaccaggaac agctgtccca cagtgtatat tccctatctt cttatacccc agatgttgca 840
tttggatcca aagattctgg tactcttcat catccccatc atcaccactc tgttccacat 900
cagccagata acttagcagc ttcaaataca caatctgaag gatcagactc tgtgatttta 960
ctgaaagtga aagattccca gactccaact cccagttcta ctttcttcca ggcagagctg 1020
tggatcaaag aattaactag tgtttatgat tctcgagcac gagaaagatt gcgccagatt 1080
gaagaacaga aggcattggc cttacagctt caaaaccaga gattgcagga gcgggaacat 1140
tcagtacatg attcagtaga actacatctt cgtgtacctc ttgaaaagga gattcctggt 1200
actgttgtcc aagaaacaca aaaaaagggt cataaattaa ctgatagtga agatgaattt 1260
cctgaaatta cagaggaaat ggagaaagaa ataaagaatg tatttcgtaa tgggaatcag 1320
gatgaagttc tcagtgaagc atttcgctg accattacac gcaaagatat tcaaactcta 1380
aaccatctga attggctcaa tgatgagatc atcaatttct acatgaatat gctgatggag 1440
cgaagtaaa agagggtt gccagtggtg catgcattta atacctttt cttcactaaa 1500
ttaaaaacgg ctggttatca ggcagtgaaa cgttggacaa agaaagtaga tgtatcttct 1560
gttgacattc ttttggtgcc cattcacctg ggagtacact ggtgtctagc tgttgtggac 1620
tttagaaaga agaatactac ctattacgac tccatgggtg ggataaacia tgaagcctgc 1680
agaatactct tgcaatacct aaagcaagaa agcattgaca agaaaaggaa agagtttgac 1740

```

- 2 -

accaatggct ggcagctttt cagcaagaaa agccagattc ctcagcagat gaatggaagt 1800  
 gactgtggga tgtttgctg caaatatgct gactgtatta ccaaagacag accaatcaac 1860  
 ttcacacagc aacacatgcc atacttccgg aagcggatgg tctgggagat cctccaccga 1920  
 aaactcttgt ga 1932

<210> 2  
 <211> 643  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> sentrin/SUMO-specific protease 1 (SEN1)

<400> 2  
 Met Asp Asp Ile Ala Asp Arg Met Arg Met Asp Ala Gly Glu Val Thr  
   1                  5                  10                  15  
 Leu Val Asn His Asn Ser Val Phe Lys Thr His Leu Leu Pro Gln Thr  
                   20                  25                  30  
 Gly Phe Pro Glu Asp Gln Leu Ser Leu Ser Asp Gln Gln Ile Leu Ser  
           35                  40                  45  
 Ser Arg Gln Gly His Leu Asp Arg Ser Phe Thr Cys Ser Thr Arg Ser  
           50                  55                  60  
 Ala Ala Tyr Asn Pro Ser Tyr Tyr Ser Asp Asn Pro Ser Ser Asp Ser  
   65                  70                  75                  80  
 Phe Leu Gly Ser Gly Asp Leu Arg Thr Phe Gly Gln Ser Ala Asn Gly  
                   85                  90                  95  
 Gln Trp Arg Asn Ser Thr Pro Ser Ser Ser Ser Ser Leu Gln Lys Ser  
                   100                  105                  110  
 Arg Asn Ser Arg Ser Leu Tyr Leu Glu Thr Arg Lys Thr Ser Ser Gly  
           115                  120                  125  
 Leu Ser Asn Ser Phe Ala Gly Lys Ser Asn His His Cys His Val Ser  
   130                  135                  140  
 Ala Tyr Glu Lys Ser Phe Pro Ile Lys Pro Val Pro Ser Pro Ser Trp  
   145                  150                  155                  160  
 Ser Gly Ser Cys Arg Arg Ser Leu Leu Ser Pro Lys Lys Thr Gln Arg  
           165                  170                  175  
 Arg His Val Ser Thr Ala Glu Glu Thr Val Gln Glu Glu Glu Arg Glu  
           180                  185                  190  
 Ile Tyr Arg Gln Leu Leu Gln Met Val Thr Gly Lys Gln Phe Thr Ile  
           195                  200                  205  
 Ala Lys Pro Thr Thr His Phe Pro Leu His Leu Ser Arg Cys Leu Ser  
   210                  215                  220

- 3 -

Ser Ser Lys Asn Thr Leu Lys Asp Ser Leu Phe Lys Asn Gly Asn Ser  
 225 230 235 240  
 Cys Ala Ser Gln Ile Ile Gly Ser Asp Thr Ser Ser Ser Gly Ser Ala  
 245 250 255  
 Ser Ile Leu Thr Asn Gln Glu Gln Leu Ser His Ser Val Tyr Ser Leu  
 260 265 270  
 Ser Ser Tyr Thr Pro Asp Val Ala Phe Gly Ser Lys Asp Ser Gly Thr  
 275 280 285  
 Leu His His Pro His His His His Ser Val Pro His Gln Pro Asp Asn  
 290 295 300  
 Leu Ala Ala Ser Asn Thr Gln Ser Glu Gly Ser Asp Ser Val Ile Leu  
 305 310 315 320  
 Leu Lys Val Lys Asp Ser Gln Thr Pro Thr Pro Ser Ser Thr Phe Phe  
 325 330 335  
 Gln Ala Glu Leu Trp Ile Lys Glu Leu Thr Ser Val Tyr Asp Ser Arg  
 340 345 350  
 Ala Arg Glu Arg Leu Arg Gln Ile Glu Glu Gln Lys Ala Leu Ala Leu  
 355 360 365  
 Gln Leu Gln Asn Gln Arg Leu Gln Glu Arg Glu His Ser Val His Asp  
 370 375 380  
 Ser Val Glu Leu His Leu Arg Val Pro Leu Glu Lys Glu Ile Pro Val  
 385 390 395 400  
 Thr Val Val Gln Glu Thr Gln Lys Lys Gly His Lys Leu Thr Asp Ser  
 405 410 415  
 Glu Asp Glu Phe Pro Glu Ile Thr Glu Glu Met Glu Lys Glu Ile Lys  
 420 425 430  
 Asn Val Phe Arg Asn Gly Asn Gln Asp Glu Val Leu Ser Glu Ala Phe  
 435 440 445  
 Arg Leu Thr Ile Thr Arg Lys Asp Ile Gln Thr Leu Asn His Leu Asn  
 450 455 460  
 Trp Leu Asn Asp Glu Ile Ile Asn Phe Tyr Met Asn Met Leu Met Glu  
 465 470 475 480  
 Arg Ser Lys Glu Lys Gly Leu Pro Ser Val His Ala Phe Asn Thr Phe  
 485 490 495  
 Phe Phe Thr Lys Leu Lys Thr Ala Gly Tyr Gln Ala Val Lys Arg Trp  
 500 505 510  
 Thr Lys Lys Val Asp Val Phe Ser Val Asp Ile Leu Leu Val Pro Ile  
 515 520 525

- 4 -

His Leu Gly Val His Trp Cys Leu Ala Val Val Asp Phe Arg Lys Lys  
 530 535 540

Asn Ile Thr Tyr Tyr Asp Ser Met Gly Gly Ile Asn Asn Glu Ala Cys  
 545 550 555 560

Arg Ile Leu Leu Gln Tyr Leu Lys Gln Glu Ser Ile Asp Lys Lys Arg  
 565 570 575

Lys Glu Phe Asp Thr Asn Gly Trp Gln Leu Phe Ser Lys Lys Ser Gln  
 580 585 590

Ile Pro Gln Gln Met Asn Gly Ser Asp Cys Gly Met Phe Ala Cys Lys  
 595 600 605

Tyr Ala Asp Cys Ile Thr Lys Asp Arg Pro Ile Asn Phe Thr Gln Gln  
 610 615 620

His Met Pro Tyr Phe Arg Lys Arg Met Val Trp Glu Ile Leu His Arg  
 625 630 635 640

Lys Leu Leu

<210> 3

<211> 1132

<212> PRT

<213> Homo sapiens

<220>

<223> human telomerase reverse transcriptase (TERT)

<400> 3

Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser  
 1 5 10 15

His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly  
 20 25 30

Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg  
 35 40 45

Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro  
 50 55 60

Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu  
 65 70 75 80

Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val  
 85 90 95

Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro  
 100 105 110

Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr  
 115 120 125

- 5 -

Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val  
 130 135 140

Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val  
 145 150 155 160

Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr  
 165 170 175

Gln Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly  
 180 185 190

Pro Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val Arg  
 195 200 205

Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg  
 210 215 220

Gly Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg  
 225 230 235 240

Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp  
 245 250 255

Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val  
 260 265 270

Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala  
 275 280 285

Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His  
 290 295 300

Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro  
 305 310 315 320

Cys Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly  
 325 330 335

Asp Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro  
 340 345 350

Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser  
 355 360 365

Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro Gln  
 370 375 380

Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His  
 385 390 395 400

Ala Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg  
 405 410 415

Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln  
 420 425 430

- 6 -

Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu  
 435 440 445

Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe  
 450 455 460

Val Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser  
 465 470 475 480

Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser  
 485 490 495

Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met  
 500 505 510

Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys  
 515 520 525

Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe  
 530 535 540

Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe  
 545 550 555 560

Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr  
 565 570 575

Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His  
 580 585 590

Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln  
 595 600 605

His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile  
 610 615 620

Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val  
 625 630 635 640

Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser  
 645 650 655

Arg Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg  
 660 665 670

Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg  
 675 680 685

Ala Trp Arg Thr Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro  
 690 695 700

Glu Leu Tyr Phe Val Lys Val Asp Val Thr Gly Ala Tyr Asp Thr Ile  
 705 710 715 720

Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln  
 725 730 735

- 7 -

Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala His  
 740 745 750

Gly His Val Arg Lys Ala Phe Lys Ser His Val Ser Thr Leu Thr Asp  
 755 760 765

Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser  
 770 775 780

Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu  
 785 790 795 800

Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Met Cys His His  
 805 810 815

Ala Val Arg Ile Arg Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro  
 820 825 830

Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp  
 835 840 845

Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu Leu  
 850 855 860

Arg Leu Val Asp Asp Phe Leu Leu Val Thr Pro His Leu Thr His Ala  
 865 870 875 880

Lys Thr Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys  
 885 890 895

Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu  
 900 905 910

Ala Leu Gly Gly Thr Ala Phe Val Gln Met Pro Ala His Gly Leu Phe  
 915 920 925

Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser  
 930 935 940

Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe  
 945 950 955 960

Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly  
 965 970 975

Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp Leu Gln Val Asn  
 980 985 990

Ser Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile Leu Leu Leu Gln  
 995 1000 1005

Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln Gln  
 1010 1015 1020

Val Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile Ser Asp Thr Ala  
 1025 1030 1035 1040

Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met Ser Leu  
 1045 1050 1055

Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala Val Gln Trp  
 1060 1065 1070

Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg His Arg Val Thr  
 1075 1080 1085

Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr Ala Gln Thr Gln Leu Ser  
 1090 1095 1100

Arg Lys Leu Pro Gly Thr Thr Leu Thr Ala Leu Glu Ala Ala Ala Asn  
 1105 1110 1115 1120

Pro Ala Leu Pro Ser Asp Phe Lys Thr Ile Leu Asp  
 1125 1130

<210> 4  
 <211> 4015  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> human telomerase reverse transcriptase (TERT)

<400> 4  
 gcagcgtgc gtctgctgc gcacgtggga agccctggcc ccggccacc ccgcgatgcc 60  
 gcgcgtccc cgtgcccag ccgtgcgctc cctgctgcgc agccactacc gcgaggtgct 120  
 gccgctggcc acgttcgtgc ggcgcctggg gccccagggc tggcggctgg tgcagcggcg 180  
 ggaccggcg gctttccgcg cgctggtggc ccagtgcctg gtgtgcgtgc cctgggacgc 240  
 acggccgcc cccgccgcc cctccttccg ccagggtgtcc tgcctgaagg agctggtggc 300  
 ccgagtgtg cagaggctgt gcgagcgcg cgcaagaac gtgctggcct tgggcttgcg 360  
 gctgctggac ggggcccgcg ggggcccccc cgaggccttc accaccagcg tgcgcagcta 420  
 cctgcccaac acgtgaccg acgcaactgcg ggggagcggg gcgtggggggc tgctgctgcg 480  
 ccgcgtggg gacgacgtgc tggttcacct gctggcacgc tgcgcgtctt ttgtgctggt 540  
 ggctcccagc tgcgcctacc aggtgtgcgg gccgcgcgtg taccagctcg gcgctgccac 600  
 tcaggcccgg cccccgccac acgctagtgg accccgaagg cgtctgggat gcgaacgggc 660  
 ctggaaccat agcgtcaggg aggccggggt ccccctgggc ctgccagccc cgggtgcgag 720  
 gaggcgcggg ggcagtgcc gccaagtct gccgttgccc aagaggcca ggcgtggcgc 780  
 tgcccctgag ccggagcggg cggccgttgg gcaggggtcc tgggcccacc cgggcaggac 840  
 gcgtggaccg agtgaccgtg gtttctgtgt ggtgtcacct gccagaccgc ccgaagaagc 900  
 cacctctttg gaggggtgcg tctctggcac gcgccactcc caccatccg tgggcccgca 960  
 gcaccacgcg ggccccccat ccacatcgcg gccaccacgt ccctgggaca cgccttgtcc 1020  
 cccgggtgtac gccgagacca agcacttcct ctactcctca ggcgacaagg agcagctgcg 1080  
 gccctcctc ctactcagct ctctgaggcc cagcctgact ggcgctcgga ggctcgtgga 1140  
 gaccatcttt ctgggttcca ggcctggat gccagggact ccccgcagg tgcctcgcct 1200  
 gccccagcgc tactggcaaa tgcggcccct gtttctggag ctgcttggga accacgcgca 1260  
 gtgcccctac ggggtgctcc tcaagacgca ctgcccgcgt gcgagctgcg tcacccagc 1320  
 agccgggtgc tgtgcccggg agaagcccca gggctctgtg gcggcccccc aggaggagga 1380  
 cacagacccc cgtgccttgg tgcagctgct ccgccagcac agcagcccct ggcaggtgta 1440  
 cggcttcgtg cgggctgcc tgcgccggct ggtgccccca ggcctctggg gctccaggca 1500  
 caacgaacgc cgttcctca ggaacaccaa gaagtcatc tccctgggga agcatgccaa 1560  
 gctctcgtg caggagctga cgtggaagat gagcgtgcgg gactgcgctt ggctgcgag 1620  
 gagcccaggg gttggctgtg ttccggccgc agagcaccgt ctgcgtgagg agatcctggc 1680

caagttcctg	cactggctga	tgagtgtgta	cgctcgtcgag	ctgctcaggt	ctttctttta	1740
tgtcacggag	accacgtttc	aaaagaacag	gctctttttc	taccggaaga	gtgtctggag	1800
caagttgcaa	agcattggaa	tcagacagca	cttgaagagg	gtgcagctgc	gggagctgtc	1860
ggaagcagag	gtcaggcagc	atcggaagc	caggccccgc	ctgctgacgt	ccagactccg	1920
cttcatcccc	aagcctgacg	ggctgcgccc	gattgtgaac	atggactacg	tcgtgggagc	1980
cagaacgttc	cgcagagaaa	agagggccga	gcgtctcacc	tcgaggggtga	aggcactggt	2040
cagcgtgctc	aactacgagc	gggcgcggcg	ccccggcctc	ctggggcgcct	ctgtgctggg	2100
cctggacgat	atccacaggg	cctggcgcac	cttcgtgctg	cgtgtgcggg	cccaggaccc	2160
gccgcctgag	ctgtactttg	tcaaggtgga	tgtgacgggc	gcgtacgaca	ccatccccca	2220
ggacaggctc	acggagggtca	tcgccagcat	catcaaacc	cagaacacgt	actgctgctg	2280
tcggatgccc	gtggctccaga	aggccgcca	tgggcacgtc	cgcaaggcct	tcaagagcca	2340
cgctcttacc	ttgacagacc	tccagccgta	catgagacag	tcctccctga	actgagcagga	2400
gaccagcccg	ctgagggatg	ccgtcgtcat	cgagcagagc	tcctccctga	atgaggccag	2460
cagtggcctc	ttcgacgtct	tcttacgctt	catgtgccac	cacgccgtgc	gcatcagggg	2520
caagtcctac	gtccagtgcc	aggggatccc	gcagggctcc	atcctctcca	cgctgctctg	2580
cagcctgtgc	tacggcgaca	tggagaacaa	gctgtttgcg	gggattcggc	gggacgggct	2640
gctcctgcgt	ttgggtggatg	atctctgtt	ggtgacacct	cacctcacc	acgcgaaaac	2700
cttctcagg	accctggctc	gaggtgtccc	tgagtatggc	tgctgtgtga	acttgccgaa	2760
gacagtgggtg	aacttcctg	tagaagacga	ggcctgggt	ggcacggctt	ttgttcagat	2820
gccggcccac	ggcctattcc	cctgggtgcgg	cctgctgctg	gatacccgga	ccctggagggt	2880
gcagagcgac	tactccagct	atgcccgac	ctccatcaga	gccagtctca	ccttcaaccg	2940
cggcttcaag	gctgggagga	acatgcgtcg	caaactcttt	gggtcttgc	ggctgaagtg	3000
tcacagcctg	tttctggatt	tgacaggtga	cagcctccag	acggtgtgca	ccaacatcta	3060
caagatcctc	ctgctgcagg	cgtaacaggt	tcacgcatgt	gtgctgcagc	tcccatctca	3120
tcagcaagtt	tggagaacc	ccacatctt	cctgcgcgtc	atctctgaca	cggcctccct	3180
ctgctactcc	atcctgaaag	ccaagaacgc	agggatgtcg	ctgggggcca	agggcggcgc	3240
cggccctctg	ccctccgagg	ccgtgcagtg	gctgtgccac	caagcattcc	tgctcaagct	3300
gactgcagac	cgtgtcacct	acgtgccact	cctggggctca	ctcaggacag	cccagacgca	3360
gctgagtcgg	aagctcccgg	ggacgacgct	gactgccctg	gaggccgcag	ccaacccggc	3420
actgccctca	gacttcaaga	ccatcctgga	ctgatggcca	cccgccaca	gccaggccga	3480
gagcagacac	cagcagccct	gtcacgccgg	gctctacgtc	ccagggaggg	aggggcggcc	3540
cacaccaggg	cccgcaccgc	tgggagtctg	aggcctgagt	gagtgtttgg	ccgaggcctg	3600
catgtccggc	tgaaggctga	gtgtccggct	gaggcctgag	cgagtgtcca	gccaagggct	3660
gagtgtccag	cacacctgcc	gtcttcaact	ccccacaggc	tggcgctcgg	ctccaccca	3720
gggccagctt	ttctcacca	ggagcccggc	ttccactccc	cacataggaa	tagtccatcc	3780
ccagattcgc	cattgttcac	ccctcgccct	gccctccttt	gccttcacc	cccaccatcc	3840
aggtggagac	cctgagaagg	accctgggag	ctctgggaat	ttggagtgtg	caaaggtgtg	3900
ccctgtacac	agggcaggac	cctgcacctg	gatgggggtc	cctgtgggtc	aaattggggg	3960
gaggtgctgt	gggagtaaaa	tactgaatat	atgagttttt	cagttttgaa	aaaaa	4015

<210> 5  
 <211> 451  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> human telomerase RNA component (TERC)

<400> 5	gggttgccgga	gggtgggcct	gggaggggtg	gtggccatct	tttgtctaac	cctaactgag	60
	aagggcgtag	gcgccgtgct	tttgcctccc	gcgcgctggt	tttctcgtg	actttcagcg	120
	ggcggaaaag	cctcggcctg	ccgccttcca	ccgttcattc	tagagcaaac	aaaaaatgtc	180
	agctgctggc	ccgttcgcc	ctcccgggga	cctgcggcgg	gtcgcctgcc	cagcccccca	240
	acccgcctg	gaggccgcgg	tcggcccggg	gcttctcgg	aggcaccac	tgccaccgcg	300
	aagagtggg	ctctgtcagc	cgccgggtctc	tcgggggcca	gggcgaggtt	caggcctttc	360

- 10 -

aggccgcagg aagaggaacg gagcgagtcc ccgcgcgcgg cgcgattccc tgagctgtgg 420  
gacgtgcacc caggactcgg ctcacacatg c 451

<210> 6  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SENP1 forward  
"sense" primer

<400> 6  
caagaagtgc agcttataat ccaa 24

<210> 7  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SENP1 reverse  
"antisense" primer

<400> 7  
gtcttttcggg tttcggagta a 21

<210> 8  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SENP1 TaqMan probe

<400> 8  
ctcagacagt tttcttggt caggcg 26

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PPP1CA forward  
primer

<400> 9  
gagcacacca ggtggtagaa 20

<210> 10  
<211> 19

- 11 -

<212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PPP1CA reverse primer

<400> 10  
 gggcttgagg atctggaaa 19

<210> 11  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PPP1CA probe

<400> 11  
 gagtttgaca atgctggcgc catgatgagt 30

<210> 12  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:substrate/inhibitor specific for SENP1 protease, SENP1 antagonist

<400> 12  
 Glu Gln Thr Gly Gly  
 1 5

<210> 13  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:nuclear localization signal sequence (NLS1)

<400> 13  
 Pro Lys Lys Thr Gln Arg Arg  
 1 5

<210> 14  
 <211> 22  
 <212> PRT  
 <213> Artificial Sequence

- 12 -

&lt;220&gt;

<223> Description of Artificial Sequence:small  
ubiquitin-like modifier (SUMO) protein Sm31  
C-terminal sequence

&lt;400&gt; 14

Thr Ile Asp Val Phe Gln Gln Gln Thr Gly Gly Val Pro Glu Ser Ser  
1 5 10 15

Leu Ala Gly His Ser Phe  
20

&lt;210&gt; 15

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:small  
ubiquitin-like modifier (SUMO) protein Sm32  
C-terminal sequence

&lt;400&gt; 15

Thr Ile Asp Val Phe Gln Gln Gln Thr Gly Gly Val Tyr  
1 5 10

&lt;210&gt; 16

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:small  
ubiquitin-like modifier (SUMO) protein Sm33  
C-terminal sequence

&lt;400&gt; 16

Val Ile Glu Val Tyr Gln Glu Gln Thr Gly Gly His Ser Thr Val  
1 5 10 15

&lt;210&gt; 17

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:small  
ubiquitin-like modifier (SUMO) protein Smt3  
C-terminal sequence

&lt;400&gt; 17

Ile Ile Glu Ala His Arg Glu Gln Ile Gly Gly Ala Thr Tyr  
1 5 10

- 13 -

<210> 18  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:TERT forward  
primer

<400> 18  
tgggcacgtc cgca 14

<210> 19  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:TERT reverse  
primer

<400> 19  
ggcgtggtgg cacatgaa 18

<210> 20  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:TERT TaqMan  
probe

<400> 20  
tcatcgagca gagctcctcc ctgaatgagg 30

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/004839

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C12Q1/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, Sequence Search		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/031411 A (ONCOTHERAPY SCIENCE, INC; JAPAN AS REPRESENTED BY THE PRESIDENT OF THE) 15 April 2004 (2004-04-15) PNC425 = SENP1 page 80	1-50
X	WO 01/22920 A (HUMAN GENOME SCIENCES, INC; RUBEN, STEVEN, M; BARASH, STEVEN, C; BIRSE) 5 April 2001 (2001-04-05) Human colon cancer antigen encoding cDNA SEQ ID NO:1655 corresponds 100% to SENP1 between nt 427-789.	1-50
X	US 6 596 527 B1 (YEH EDWARD T. H ET AL) 22 July 2003 (2003-07-22) Sequence 1 from patent US 6596527 = SENP1 column 3; claims 1-8	49,50
----- -/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
° Special categories of cited documents :		
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
*E* earlier document but published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.	
*O* document referring to an oral disclosure, use, exhibition or other means	*8* document member of the same patent family	
*P* document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search  <p style="text-align: center;">12 October 2005</p>	Date of mailing of the international search report  <p style="text-align: center;">18/10/2005</p>	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  <p style="text-align: center;">Gabriels, J</p>	

**INTERNATIONAL SEARCH REPORT**

International Application No  
PCT/EP2005/004839

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/09292 A (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 8 February 2001 (2001-02-08) Sequence 1 from Patent W00109292 = SENP1 claim 14 -----	30-39
X	US 2004/029114 A1 (MACK DAVID H ET AL) 12 February 2004 (2004-02-12) AA700122 Hs.3355 sentrin-specific protease page 52; table 4 -----	1-50
X	WO 2004/031414 A (ONCOTHERAPY SCIENCE, INC; JAPAN AS REPRESENTED BY THE PRESIDENT OF THE) 15 April 2004 (2004-04-15) PCR406 on p55 is SENP1 -----	1-50
X	EP 1 108 789 A (F. HOFFMANN-LA ROCHE AG) 20 June 2001 (2001-06-20) example 4 -----	28-32,40
P, X	WO 2004/048938 A (PROTEIN DESIGN LABS, INC; AZIZ, NATASHA; GINSBURG, WENDY, M; ZLOTNIK,) 10 June 2004 (2004-06-10) Human soft tissue sarcoma-upregulated DNA - SEQ ID 2907. Example 2; SEQ ID NO 2907 = SENP1 the whole document -----	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/004839

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
WO 2004031411	A	15-04-2004	AU 2003260966 A1	23-04-2004
			AU 2003263603 A1	23-04-2004
			CA 2500472 A1	15-04-2004
			CA 2500482 A1	15-04-2004
			EP 1556518 A2	27-07-2005
			EP 1549771 A2	06-07-2005
			WO 2004031412 A2	15-04-2004
<hr/>				
WO 0122920	A	05-04-2001	AU 7721500 A	30-04-2001
			CA 2384713 A1	05-04-2001
			EP 1265582 A2	18-12-2002
<hr/>				
US 6596527	B1	22-07-2003	NONE	
<hr/>				
WO 0109292	A	08-02-2001	AT 281522 T	15-11-2004
			CA 2387655 A1	08-02-2001
			DE 60015559 D1	09-12-2004
			EP 1204746 A2	15-05-2002
			JP 2003506032 T	18-02-2003
<hr/>				
US 2004029114	A1	12-02-2004	NONE	
<hr/>				
WO 2004031414	A	15-04-2004	AU 2003263611 A1	23-04-2004
			AU 2003264881 A1	23-04-2004
			CA 2500859 A1	15-04-2004
			CA 2500861 A1	15-04-2004
			EP 1546411 A2	29-06-2005
			EP 1546197 A2	29-06-2005
			WO 2004031231 A2	15-04-2004
<hr/>				
EP 1108789	A	20-06-2001	JP 2001204483 A	31-07-2001
			US 6664046 B1	16-12-2003
<hr/>				
WO 2004048938	A	10-06-2004	AU 2003298786 A1	18-06-2004